cluster,concept,cuis
806,no ascvd + additional cv risk factors  n ( % ),C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
806,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
806,cv risk factor,C0035648;C3538987;C4048877;C4318503
805,aspirin use ( > nmbr mg ),C0004057;C0024671;C0026410;C0042153;C0053917;C0439269;C0457083;C1334884;C1947944;C1960952;C2346927;C4321396;C4521761
804,medically important infectionsa,C3898777;C4084912
803,qualifying hbanmbrc ( % ),C1514624
802,time of symptom onset to randomization ( hrs ),C1320528
801,coexisting conditions,C0679225
800,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
800,stroke or tia — no . ( % ),C0038454;C4554100
800,stroke or pvd  ( % ),C0038454;C4554100
800,stroke ( vs tia ),C0038454;C4554100
800,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
800,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
799,type of event — no . ( % ),C1561488
799,qualifying nstemi  n ( % ),C1514624;C3537184;C4255010
798,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
798,pulmonary function tests  % of predicted,C0024119;C0681842;C1882327;C2598152
797,chanmbrdsnmbr - vasc score ( median  iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
796,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
795,preoperative heart rate ( beats per minute ),C0018810;C0445204
795,heart rate ( b . p . m . )  mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
795,heart rate  mean ± sd ( b . p . m . ),C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
795,baseline heart rate,C0018810;C0168634;C1442488
794,previous oral glucose - lowering agents  % of patients,C0205156;C0441994;C0600419;C1552607;C1955477;C2003888
794,presence of dactylitis  n ( % ),C0150312;C0239161;C0392148;C3854307
793,st - segment elevation mi,C0520886;C3810814
793,paclitaxel - eluting,C0144576
792,alcohol use ( > nmbr drink / wk ),C0001948;C0042153;C0053917;C0332174;C0439230;C0452428;C0457083;C0556297;C1334884;C1947944
791,previous hf hospitalization  n ( % ),C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
791,no prior hf hospitalization ( n = nmbr  nmbr ),C0018488;C0019993;C0053917;C0332152;C1313497;C1334884;C1538440;C2826257;C3273279
791,hosp . for hf,C0018488;C1313497;C1538440;C3273279
791,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
791,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
790,lipid - lowering therapy,C0585943
789,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
788,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
788,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
788,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
788,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
788,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
788,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
787,history of peripheral vascular disease,C1881056
786,past or current angina pectoris,C1444637;C4284302
785,gender  women n  % ),C0043210;C0079399;C1522384
785,gender  % of patients,C0030705;C0079399;C1522384
785,eze / simva gender,C0079399;C1522384
784,vascular territory # nmbr,C0005847;C0053917;C1301808;C1334884;C1558950;C1801960;C2983136
784,nmbr vessels or left main,C0005847;C0053917;C1334884
783,demographic characteristics,C0683970
782,difference ( a ) vs placebo ( nmbr % cl ),C1705241;C1705242
781,fevnmbr % reversibility,C0449261
780,primary prevention subgroup,C0033144;C1079230;C1515021
780,disease duration  median ( range ) years,C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
779,o total randomized,C0439175;C0439810;C0483204
778,laba / lama,C0999593;C1416775
778,genotyping,C1285573
777,ff / vi nmbr / nmbr pg od,C0030827;C0053917;C0072225;C0205999;C0229089;C0439164;C1266240;C1334884;C1512019;C3273373;C3665488;C4554348
776,unknown,C0439673;C3541433;C4050014
775,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
774,p value for adjusted hr,C0456081;C1709380
773,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
772,haemodynamics and lv function,C0019010;C4281788
771,primary end point kaplan - meier rate  %,C0871208;C1521828;C2986535
771,lower - limb arterial — no . ( % ),C0023216
770,sex : male ( n = nmbr ),C0053917;C0086582;C1334884
770,sex  n ( % ) male,C0086582
770,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
769,active or previous cancer,C0205177;C3853793;C3888249
768,dual antiplatelet,C0205173;C1554184
767,fatal and nonfatal stroke,C1302234;C1705232
766,procedure,C0184661;C2700391;C3274430;C3539779
766,proactive intervention ( n = nmbra ),C0184661;C0886296;C1273869
766,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
766,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
766,multivessel intervention  n ( % ),C0184661;C0886296;C1273869
765,duration of tnmbrdm  y,C0449238;C2926735
765,active a,C0205177;C3853793;C3888249
764,responders of three - item end point at nmbr weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
763,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
763,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
762,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
762,free fatty acids ( mmol / l ),C0015688;C1532563
761,ccv history / condition,C0683519
760,stroke risk score,C0449820;C1277291;C4050231
759,rivaroxaban + aspirin,C0004057;C1739768
759,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
759,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
759,aspirin but no ppi,C0004057
759,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
759,aspirin and ppi,C0004057
759,aspirin and other antiplatelet,C0004057
759,aspirin / other antiplatelet agents  n ( % ),C0004057
759,aspirin / antiplatelet,C0004057
758,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
758,white  n ( % ),C0007457;C0043157;C0220938
758,caucasian simva,C0007457;C0043157
758,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
757,type of des,C0011702;C0332307;C1547052;C4551552
757,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
756,oral aminosalicylates,C0368663;C0442027;C4521986
755,history of microvascular eye disease 本  n ( % ),C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
754,stiffness subscale,C0427008
753,received an oral aha within nmbr weeks prior to screening,C1514756
752,thrombocytopenia,C0040034;C0392386
752,profound thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0392386;C0439808
752,moderate thrombocytopenia ( < nmbrxnmbr / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
751,musculoskeletal,C0497254;C2707260
750,duration of disease  years,C0439234;C0872146
749,current drinker,C0556297
748,native coronary - artery lesions,C0205042;C0221198;C0302891
747,week nmbr ( geometric mean  cv ),C0053917;C0332174;C0439230;C1334884;C2986759;C3538987;C4048877;C4318503
747,timi risk score nmbr - nmbr,C0035647;C0053917;C0449820;C1334884;C4050231;C4552904
747,framingham nmbr - year cv risk score,C0035647;C0053917;C0439234;C0439508;C0449820;C1334884;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
747,> nmbr additional cv risk factorsnmbr,C0035647;C0053917;C1334884;C1524062;C3538987;C4048877;C4318503;C4552904
746,perianal or anus,C0442158
745,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
744,liraglutide nmbr . nmbr mg / day ( n = nmbr ),C0053917;C0439422;C1334884;C1456408
744,liraglutide ( n = nmbr  nmbr ),C0053917;C1334884;C1456408
743,peripheral vasodilators,C0724804
742,das - nmbr ( crp ) < nmbr . nmbr  n ( % ),C0051767;C0053917;C0057671;C1334884;C3890735;C4048285
741,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
741,no corticosteroid + no imm  n,C0001617;C3536709
741,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
740,current or previous atrial fibrillation,C0521116;C1705970
739,history of percutaneous coronary intervention,C1320647;C4554713
738,mean ( sd ) post - bronchodilator fevnmbr reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239
737,enalapril + aliskiren dm = nmbr non - dm = nmbr,C0011816;C0014025;C0053917;C1120110;C1334884;C1518422;C3250443
736,crp ( mg / l )  median ( min  max ),C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285
735,prior implantable cardiodefibrillator  n ( % ),C0021102;C0332152;C2826257
734,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
733,urine albumin - to - creatinine ratio,C0455271;C1318330
732,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
731,menopausal status and use of hrt ( % ) y,C1513126
730,lvef ( % )  mean ± sd,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
730,european union,C0015179
729,abatacept monotherapy ( n = nmbr ),C0053917;C1334884;C1619966
729,abatacept ( n = nmbr * ),C0053917;C1334884;C1619966
728,clinical criterianmbr,C0205210
727,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
726,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
725,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
724,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
724,concomitant therapy,C1707479
724,accp bleeding risk at inclusion  no . ( % ) f,C0007637;C1512693;C3251812
723,micro - / macro - albuminuria  ckd and / or retinopathy,C0001925;C0085672;C1553035;C1561643;C2984010;C3811161;C4049106
723,any albuminuria — no . ( % ),C0001925
723,albuminuria ( g / g ),C0001925;C1319635
722,screening prebronchodilator fevnmbr  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
722,screening bmi ( kg / mnmbr ),C0022718;C0220908;C0220909;C0439209;C0578022;C1698960;C1710031;C1710032;C1710477;C2348164;C4054209
722,screening % reversibility fevnmbr,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164
722,screening % predicted fevnmbr,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164
722,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
722,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
721,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
720,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
719,low hdl cholesterol,C0151691
718,current medication — no . ( % ),C0746467
717,dyspepsia,C0013395;C4552968
717,clinical and laboratory measurements,C0205210
716,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
716,rheumatoid factor positive §  n ( % ),C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
716,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
716,rf positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
716,rf positive  %,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
716,rf and acpa negativenmbr,C0035448;C0201660;C0748398;C1547111
715,rhabdomyolysis  myopathy  or myalgia with ck elevation > nmbrx uln,C0026848;C0035410;C4552660
714,mean eosinophil count  per ml,C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665
713,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
712,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
711,systemic corticosteroids  n ( % ) a,C4053960
710,diameter stenosis  mean ( sd )  %,C0552409;C0678234;C1261287;C2632116;C2699239
710,% stenosis  as assessed by investigator,C0678234;C1261287;C2632116
709,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
708,odds ratio adj ( nmbr % cl ),C0001552;C0028873;C0053917;C0596019;C1334884;C2826286
707,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
707,erosion score  median ( min  max ),C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231
706,mini - mental state examination,C0451306
705,months since ra was first diagnosed  mean ( sd ),C0439231
704,history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,C0205267;C2315493
703,coronary bypass graft,C1260596
702,peripheral - artery disease ( % ),C1704436;C4025272
702,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
701,apob : apoa - nmbr ratio,C0003592;C0003593;C0053917;C0456603;C0523508;C1334884;C1547037;C3252643;C4553344;C4553379
700,laboratory values,C0022877;C0042295;C3244292;C4283904
700,laboratory data  mean ( sd ),C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904
700,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
699,femoral access — no . / total no . ( % ),C0015811
698,cardiac therapy  n ( % ) d,C3654025
697,cardiovascular history — no . / total no . ( % ),C1880008
696,clinical presentation,C2708283
695,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
694,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
694,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
694,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
693,other glp - nmbr receptor agonist,C0018301;C0053917;C1334884;C1422069;C1425391;C1539338;C2350813;C4543206
693,glp - nmbr receptor agonist ( other than study drug ),C0013175;C0018301;C0053917;C1334884;C1422069;C1425391;C1539338;C2350813;C4543206
692,fc - ldl - c  mg / dl,C0439269;C2983605
692,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
691,nmbrbaseline mean,C0444504;C2347634;C2348143
690,sex ( interaction : p = nmbr . nmbr ),C0009253;C0036864;C0053917;C0079399;C0804628;C1314687;C1334884;C1522384;C1704675
689,lv hypertrophy  n ( % ),C0149721
689,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
689,left ventricular hypertrophy ( % ),C0149721;C3484363
688,extensive,C0205231
687,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
687,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
686,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
685,small vessel,C0225988
684,post - menopausal ( a ),C0232970
683,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
682,initiation of dialysis  renal transplantation  or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l ),C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0589507;C1059964;C1158830;C1704686;C4551529
681,history of alcohol use,C0551571;C0552479
680,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
680,enthesitis count,C0750480;C1282952;C1705566
679,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
678,unbound pcsknmbr ( nmol / l ),C0439282
677,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
677,cor revasc,C0018787;C0056331;C0378365
676,basmi ( linear )  mean ( sd ),C0205132;C0444504;C2347634;C2348143;C2699239
675,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
674,mi or cad,C3810814
673,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
672,indian ( indian subcontinent ),C0454693
672,highest tg tertile,C0337445;C1522410
671,min  max,C0702093;C1524029;C3813700
670,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
669,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
668,prior history of cardiovascular disease  n ( % ),C0332152;C0455539;C2826257
668,estimated glomerular filtration rate - ml / min  median ( iqr ) ',C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844
668,d - dimer levelsatinclusion,C0060323
667,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
666,mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143
665,any aes  n ( % ),C1412268;C2699274
664,interaction : treatment by psoriasis p valuenmbr,C1704675;C3258078
664,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
663,nace ( primary endpoint ),C2986535
662,right ventriculardysfunction atinclusion,C0205090;C0444532
661,omega - nmbr fatty acid ( n = nmbr ),C0015684;C0053917;C1334884;C1719844
661,omega - nmbr fatty acid,C0015684;C0053917;C1334884;C1719844
661,number omega - nmbr number placeb fatty acid,C0015684;C0053917;C0237753;C0449788;C1334884;C1719844
661,b digit symbol substitution  omega - nmbr fatty acids vs placebo,C0015684;C0053917;C0582802;C0679214;C1334884;C1555721;C1698987;C1706204;C1719844;C3241971
661,a mini - mental state examination  omega - nmbr fatty acids vs placebo,C0015684;C0053917;C0451306;C1334884;C1719844
660,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
660,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
659,tnmbrdm duration ( years ),C0439234;C0449238;C2926735
659,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
658,leukocytes  nmbr / nl,C0023516;C0027778;C0053917;C0560008;C1334884;C3892223
657,pathological q waves,C0429090
656,bilateral disease ( % ) ' j ' ' j ',C1511113
655,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
654,number of pack - years,C0237753;C0449788;C1277691
653,left circumflex,C0205091;C0443246;C1552822;C1880089
653,associated with hiv infection,C0019693;C0332281
652,conventional treatment,C2945704
651,anatomic complexity characteristics,C0439855;C0502371;C1704241
650,extent of disease  n ( % ),C0449279;C4553144
649,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
649,diuretic drugs  n ( % ),C0012798;C0013227;C3687832
649,diuretic drugs,C0012798;C0013227;C3687832
648,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
647,peripheral edema,C0085649
646,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
646,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
645,joint swelling,C0152031
644,mild or moderate copd,C2945599
643,pulmonary embolism,C0034065
643,isolated pulmonary embolism,C0034065;C0205409;C1548221
643,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
642,retinopathy — %,C0035309;C1962966
641,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
641,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
641,glucose  mmol / l,C0017725;C1532563
640,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
640,blood pressure,C0005823;C1271104;C1272641
639,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
638,thrombophilia,C0398623
638,planned treatment duration  n ( % ),C4528394
637,three - vessel disease,C3272265
637,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
636,crcb - ( ml / min )  mean ( s . e . ),C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
635,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
634,prior cerebrovascular disease,C0007820;C0332152;C2826257
634,ischemic cerebrovascular disease  n ( % ),C0007820;C0475224
634,cerebrovascular disorders  n ( % ),C0007820
634,cerebrovascular disease  n ( % ),C0007820
633,before bronchodilation,C1371299;C3537072
632,warfarin ( n = nmbr ),C0043031;C0053917;C1334884
632,> nmbr yr warfarin experience,C0043031;C0053917;C0237607;C0439234;C0596545;C1334884
632,> nmbr days warfarin,C0043031;C0053917;C0439228;C1334884
631,treatment duration  days,C0439228;C0444921;C3259042
630,osteoporosis,C0029456;C4554622
629,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
629,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
629,lipoprotein ( a )  median ( ql  qnmbr )  nmol / l,C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
628,median blood eosinophil count  cells per pla,C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193
627,glomerular,C0022663;C0268731
626,hormone therapy,C0279025
625,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
624,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
623,fpg  mean ( sd )  mmol / l,C0444504;C1532563;C2347634;C2348143;C2699239
622,ipf - related,C0034069;C1800706
621,physician global assessment ( nmbr - nmbr mm vas ),C0042815;C0053917;C1334884;C3536884;C3827561;C4050369;C4330985;C4554674
621,patient global assessment of disease activity ( vas nmbr - nmbr mm ),C0042815;C0053917;C1334884;C3536884;C3827561;C4054228;C4330985;C4554674
621,pain vas  nmbr - nmbr mm,C0042815;C0053917;C1334884;C4330985;C4554674
620,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),C0008107;C0023668;C0024671;C0026410;C0053917;C0286651;C0439269;C1334884;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
619,vascular disease indicator no ( n = nmbr ),C0021212;C0042373;C1235732;C1522602
619,previous vascular disease,C0042373;C0205156;C1552607
619,other vascular disease — no . ( % ),C0042373
619,number of vessels disease,C0042373;C0237753;C0449788
619,double - vessel disease  n ( % ),C0042373;C0205173;C1705764;C1705765
618,median ( sd )  mg / mmol,C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193
618,femoral neck,C0015815
617,scr  gmol / l,C1539487;C4050416
617,% predicted pre - bronchodilator fevnmbr  % *,C0681842;C1882327;C2599602
616,troponin t,C0077404;C1420827
616,nationality,C0027473
616,alt  ast  or both > nmbrx uln,C3831581
615,apixaban vs . placebo,C1831808
615,apixaban,C1831808
614,previous balloon angioplasty  n ( % ),C0002996;C0002997;C0205156;C1552607
614,balloon angioplasty — no . ( % ),C0002996;C0002997
614,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
613,region of enrollment  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
613,region of enrollment  n ( % ) +,C0017446;C0205147;C1516879;C1696073;C3888021
613,intestinal area involved  n ( % ) $,C0017446;C0021853;C0205146
613,grouped region,C0017446;C0205147;C0439745;C4319846
613,geographical region ( % ),C0017446
613,geographic region — no . ( % ),C0017446
613,geographic region - north america,C0017446;C0028405
613,geographic region - europe,C0015176;C0017446
613,geographic region  %,C0017446
613,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
612,managed medically — no . / total no . ( % ),C1273870
611,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
610,serum sodium — meq / liter,C0439152;C0475211;C0523891
609,circumflex,C1880089
608,aortic stenosis  n ( % ),C0003507
608,aortic stenosis,C0003507
607,etanercept ( n = nmbr ),C0053917;C0717758;C1334884
607,etanercept,C0717758
606,upper gastrointestinal,C3203348
606,uacr  mg / mmol ( interquartile range ) b,C0567349;C1711350;C2348885
605,distal anastomosis ( % ),C0448964
604,vorapaxar placebo nmbr - yr . km % rate,C0032042;C0053917;C0439234;C0871208;C1334884;C1521828;C1696465;C1706408;C2974521;C3887676
604,vorapaxar placebo nmbr - yr %,C0032042;C0053917;C0439234;C1334884;C1696465;C1706408;C2974521
604,vorapaxar group ( n = nmbr ),C0053917;C0441848;C1334884;C2974521
603,isolated igt,C0205409;C1548221
602,prior congestive heart failure,C0018802;C0332152;C2826257
602,congestive heart failure — no . ( % ) | |,C0018802
602,congestive heart failure  n ( % ),C0018802
602,chronic heart failure,C0018802;C0264716
601,europe / lsrael,C0015176
601,biomarker status,C0449442
600,mean platelet volume  fl,C0200665;C0344388;C1300812;C1708024
600,history of paroxysmal atrial fibrillation  n ( % ),C0205311;C0729790
599,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
599,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
598,acute and delayed reaction,C0205178
597,prasugrel,C1620287
597,pnmbrynmbr inhibitor,C1999216
596,no . of days to homa - ir testing — median ( iqr ),C0439228
596,ancestry ( % ) f,C0016327
595,blood oxygenation  mean ± sd,C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239
594,risk reduction ( %  nmbr % ci ),C0008107;C0053917;C1137094;C1334884;C3259781
594,pav  mean ( nmbr % ci ),C0008107;C0053917;C0058890;C0444504;C1334884;C2347634;C2348143;C3259781
594,mean age  years ( nmbr % ci ),C0008107;C0053917;C0444504;C1334884;C1510829;C2347634;C2348143;C3259781
594,mean ( nmbr % ci ) difference vs saxa + dapa + met,C0008107;C0053917;C0444504;C1334884;C1705241;C1705242;C2347634;C2348143;C3259781
594,hr ( nmbr % ci ) p value for interaction *,C0008107;C0053917;C1334884;C1704675;C1709380;C3259781
594,hazard ratio for event ( nmbr % ci ),C0008107;C0053917;C0441471;C1334884;C2985465;C3259781;C4019010
594,( nmbr % ci] nmbr,C0008107;C0053917;C1334884;C3259781
594,( nmbr % ci ) p value,C0008107;C0053917;C1334884;C1709380;C3259781
593,inhaled anticholinergic §,C0004048;C0242896;C3537004
593,anti - cholinergics ( short - acting ) a,C0242896
593,anti - cholinergics ( long - acting ),C0242896
592,non – small - cell lung cancer,C0007131;C2984258;C3539721
592,current / past,C0521116;C1444637;C1705970;C4284302
591,medical history,C0262926;C1704706
590,duration of tnmbrdm ( % ),C0449238;C2926735
589,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
588,fev  at baseline,C0168634;C1442488;C3714541
588,baseline fvc  l,C0168634;C1442488;C3714541
588,baseline fev  ( l ),C0168634;C1442488;C3714541
587,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
586,dactylitis  n ( % ),C0239161
585,anticoagulant therapy,C0150457
584,intermittent claudication,C0021775
584,claudication ( fontaine class > nmbr ),C0021775;C0053917;C0311395;C0456387;C1334884;C1456822;C1518526;C1705943
584,claudication,C0021775;C0311395;C1456822
583,south asian,C1519427
582,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
581,nmbr to < nmbr kg / mnmbr,C0022718;C0053917;C0439209;C1334884;C4054209
581,nmbr - nmbr . nmbr kg / mnmbr,C0022718;C0053917;C0439209;C1334884;C4054209
581,bmi > nmbr kg / mnmbr ( % ),C0022718;C0053917;C0439209;C0578022;C1334884;C4054209
581,bmi ( kg / mnmbr ) < nmbr,C0022718;C0053917;C0439209;C0578022;C1334884;C4054209
580,yes  non - insulin - treated,C1549445;C1705108;C1710701
579,non - hdl - c ( mmol / l  mean ),C0444504;C1518422;C1532563;C2347634;C2348143;C3715113
578,history of bone disease ( predefined )  n ( % ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
577,severe hyperkalemiac,C0205082;C4050465;C4050466
576,coronary heart disease ( % ),C0010054;C0010068;C1956346
576,coronary heart disease,C0010054;C0010068;C1956346
575,serum creatinine  mean ( sd )  pmol / l,C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
574,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
573,seropositivity,C0521143
572,sf - nmbr score,C0037712;C0053917;C0449820;C1334884;C4050231
572,sf - nmbr physical component summaryjj,C0031809;C0037712;C0053917;C0205485;C0449432;C1334884;C1509143;C1705248
572,sf - nmbr ( health transition score ),C0037712;C0053917;C0376627;C0449820;C1334884;C4050231
571,extended - duration enoxaparin  n / n ( % ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
571,enoxaparin / vka,C0206460
571,enoxaparin,C0206460
570,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
570,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
570,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
570,clopidogrel no . of patients % ),C0070166
570,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
570,clopidogrel / ticlopidine,C0040207;C0070166
570,clopidogrel  ticlopidine  or prasugrel,C0040207;C0070166
570,clopidogrel  %,C0070166
569,remission  n ( % ),C0544452;C0687702
568,vitamin e,C0042874;C3714803
568,arb at enrollment,C1516879;C1696073;C3888021;C3888198
567,duration  mean ( sd )  years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
566,hypoglycaemic agents,C0020616
566,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
566,antihyperglycemic,C0020616
565,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
564,peri - op amiodarone : no ( n = nmbr ),C0002598;C0347985
564,amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0002598
564,amiodarone  n ( % ),C0002598
564,amiodarone,C0002598
563,estimated glomerular filtration rate,C3811844
562,homa - ir  median ( qnmbr  qnmbr ),C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
562,bdmard - ir,C0022065;C0022071;C1448132
561,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
561,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
560,metabolic syndrome characteristics  n ( % ),C0524620;C1521970
560,event / total,C0439175;C0439810;C0441471;C4019010
559,events  no .,C0441471;C3541888
558,history of congestive heart failure,C0455531;C0742742
557,medical history — no . / total no . ( % ),C0262926;C1704706
556,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
555,hormonal status,C0449438;C0458083
554,class i or iii aad use in nmbr months before enrollment,C0441885;C1319793;C2698967
553,ejection fraction  % nyha class  n ( % ),C0489482;C1882083;C2700378
552,emotional status,C0013987;C0449438;C0849912
552,additional investigations,C2359834
551,modmy al randcnxzaton,C0202311
550,years [range],C0439234;C1514721;C2348147;C3542016
549,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
549,large - artery atherosclerosis,C0003850;C0004153;C0226003
549,atherosclerosis^  n ( % ),C0003850;C0004153
548,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
548,previous cardiovascular disease !,C0007222;C0205156;C1552607
548,nmbr - nmbr with cv disease ( n = nmbr ),C0007222;C0053917;C1334884
548,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
548,cvd or mi,C0007222
548,cardiovascular disease,C0007222
547,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
546,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
546,fibrinogen  g / l,C0016006;C0439294;C0456615;C1167394;C2587184;C3540039
546,fibrinogen,C0016006;C1167394;C2587184;C3540039
545,laboratory measurements,C0681902
545,emergent / urgent surgery,C0750573;C2188405
544,limb ( sd ),C0015385;C2699239
543,established ascvd,C0443211;C1272684;C3665365
542,time from onset of pain to randomization  median ( iqr )  h,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
542,prior tnfi  n ( % ),C0332152;C2826257
541,functional assessment of chronic illness,C0008679;C0278372
541,dasnmbr - esr lda,C3811131;C4553195
540,terminal ileum,C0227327
539,tg  mmol / l [mg / dl],C0337445;C3642216;C3898312
539,microvascular complications  n ( % ) ’,C0009566;C0443258;C1171258
538,history of currently treated hypertension  n ( % ),C0455527;C0521116;C1522326
538,frailty status,C0424594;C0449438
537,valsartan / hctz  n / n ( % ),C0020261;C0216784
537,valsartan / hctz,C0020261;C0216784
536,total score on the sgrq - c  i ,C0021966;C0221138;C2964552;C3826872
535,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
534,fevi  l *,C0429706;C0849974;C1561566;C4528367
533,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
532,dpi ( other than diskus )  n,C1553480
531,any cardiovascular disease history  n ( % ),C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
530,concomitant therapy  no . ( % ),C1707479
530,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
529,anyantianginal agent,C0450442;C1254351;C1521826
528,left anterior descending artery  n ( % ),C0226032
527,lipid levels — mg / dl,C0428460;C0439269
527,former or never,C0205156;C0750523
527,any type  according to daily dose * *,C0332307;C0680240;C1547052;C2348070
526,without dm ( n = nmbrinmbr * ),C0011816;C3250443
526,uacra  mg / g  n ( % ),C1300563
525,cardiovascular medications  %,C0007220
525,cardiovascular medications,C0007220
524,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
523,mean fevnmbr  l ( sd ),C0444504;C2347634;C2348143;C2699239
522,intent of early invasive strategy  %,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
522,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
521,obesity ( body mass index > nmbr kg / mnmbr ),C0005893;C0022718;C0028754;C0053917;C0439209;C0578022;C1305855;C1334884;C1963185;C4054209
520,usa and canada,C0041703
520,united states,C0041703
519,class l / ll heart failure,C0456387;C1518526;C1705943
518,use of ace inhibitor,C0003015;C1524063;C4541021
518,time from onset to randomization  h  mean ± sd,C0449244
518,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
517,carotid revascularization,C0581603;C0741968
516,mean hscrp  mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239
515,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
514,therapy ( asa nmbr / placebo nmbr ),C0004057;C0032042;C0039798;C0053917;C0087111;C1334884;C1363945;C1696465;C1706408;C3853627
514,therapy ( asa nmbr  nmbr / placebo nmbr ),C0004057;C0032042;C0039798;C0053917;C0087111;C1334884;C1363945;C1696465;C1706408;C3853627
514,events treatment ( nmbr ),C0039798;C0053917;C0087111;C0441471;C1334884;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
514,epa treatment ( n = nmbr ),C0039798;C0053917;C0087111;C1334884;C1522326;C1533734;C1705169;C3538994;C3887704
514,dpp - nmbr inhibitor therapy,C0039798;C0053917;C0087111;C1334884;C1363945;C1414174;C1999216
513,homajr tx difference vs pbo  median change from baseline ( se ) nmbr lipid parameters,C0041403;C1705241;C1705242
513,homa_ % b tx difference vs pbo  median change from baseline ( se ) nmbr,C0041403;C1705241;C1705242
512,one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr,C0205447
511,mycophenolate mofetil,C0209368
511,mean ( sd ) crp  mg / l *,C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
510,triple - vessel disease  n ( % ),C0856738
509,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
509,fish oil,C0016157
508,mdi / hfa  n,C0015458;C0993596;C1839839;C4049613
507,native latin,C0302891
506,persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,C0019046;C0021966;C0053917;C0221138;C0439234;C0741008;C1334884;C1549954
506,"nmbr - aminosalicylates ’ i "" i ‘",C0021966;C0053917;C0221138;C0368663;C1334884
506,i & ii : fevnmbr > nmbr % predicted,C0021966;C0053917;C0221138;C1334884;C1710602;C4082587
506,estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §,C0021966;C0023806;C0053917;C0221138;C0439445;C0702093;C1334884;C1524029;C3811844;C3813700
505,indication for pci,C0392360;C3146298;C4049621
504,median ( iqr ) age  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
503,established ascvd or > nmbr cv risk factors,C0443211;C1272684;C3665365
502,vertebrobasilar infarct,C0021308;C0545733
502,infarct characteristics,C0021308;C1521970
502,any relevant infarct,C0021308;C2347946
501,other lipid - modifying drug use at study entry  n ( % ),C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
500,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
499,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
499,weight  median ( interquartile range )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209
499,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
499,mean weight  kg ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
498,prior ischemic stroke,C0332152;C0948008;C2826257
498,hydralazine,C0020223
497,abatacept / open - label abatacept,C1619966;C1709323
496,copd - rosuvastatin ( n = nmbr ),C0024117;C0053917;C0965129;C1334884;C1412502;C3714496
495,central / eastern europe and russia hr ( nmbr % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
495,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
494,adverse outcome,C1274040
493,discontinuations teaes,C0457454
492,no . of prior tnfi,C0332152;C2826257
491,isolated systolic hypertension  n ( % ) “,C0745133
490,smoking history  pack - years  mean ( sd ),C0444504;C1277691;C1519384;C2347634;C2348143;C2699239
489,prior surgery : no,C0455610
488,current ( nmbr + cigs / day ),C0053917;C0332173;C0439228;C0439505;C0521116;C1334884;C1570610;C1705970
488,current (  nmbr cigs / day ),C0053917;C0332173;C0439228;C0439505;C0521116;C1334884;C1570610;C1705970
487,emotional well - being,C2984554;C3641833
486,multiple,C0439064
485,zotarolimus - eluting,C1700035
485,black race,C0005680
485,angina class iii or iv prior myocardial infarction,C0264677
484,men  total ( n 二 nmbr ),C0025266;C0053917;C0439175;C0439810;C1334884
484,hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,C0025266;C0043210;C0053917;C1334884;C3642216;C3715113;C3898312
483,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
483,oad plus insulin,C0021641;C1533581;C1579433;C3714501
482,formal education  years,C0439234;C0681344
481,one - third radius,C0034627;C0205437;C0205447;C1306504
481,enalapril,C0014025
481,elevated tg,C0205250;C0337445;C3163633
480,race or ethnic group ( % ),C0034510;C1706779;C3853635
480,race or ethnic group,C0034510;C1706779;C3853635
480,race and ss at baseline,C0034510;C1706779;C3853635
480,race - non - white ( n = nmbr  nmbr ),C0034510;C1706779;C3853635
480,race  white  n ( % ),C0034510;C1706779;C3853635
479,combined end points,C0205195;C2349179
478,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
477,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
476,post - bronchodilator fevnmbr ( % predicted * ),C2599594
476,nonaspirin antiplatelet agent,C0085826;C0722138
476,median ( qnmbr : qnmbr ) total daily insulin dosenmbr,C0021641;C0332173;C0439175;C0439810;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
475,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
474,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
473,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
473,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
473,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
472,age  mean years  [sd],C0444504;C1510829;C2347634;C2348143;C2699239
471,total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439810;C1333400
471,acc / aha lesion class bnmbr or c  n ( % ),C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
470,standard therapy,C2936643
470,history of hypercholesterolemia  n ( % ),C1533076
469,patients ' characteristics age ( years )  mean + sd,C0444504;C0815172;C1510829;C2347634;C2348143;C2699239
469,abx - facil . pci,C4049621
468,cardiac rhythm,C0232187
467,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
467,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
467,copd or asthma,C0024117;C1412502;C3714496
467,chronic obstructive pulmonary disease  n ( % ),C0024117
467,chronic obstructive pulmonary disease,C0024117
466,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
466,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
465,amlodipine nmbrmg / v = nmbr,C0051696;C0053917;C1334884
465,amlodipine / vaisartan ( n = nmbr ),C0051696;C0053917;C1334884
464,parameter,C0549193;C1704769;C2350001
464,mucolytic agent,C0026698
463,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
463,immunomodulatory agents,C0005525
462,unacceptable adverse events,C0877248;C1705413;C1883420
461,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
461,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
461,death or absolute fvc decrease > nmbr %,C0011065;C1306577;C4082313;C4552775
461,death  mi  idr  or st,C0011065;C1306577;C3810814;C4082313;C4552775
461,death  large mi,C0011065;C0549177;C1306577;C3810814;C4082313;C4552775
460,oral hypoglycemic agent,C0359086
459,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
459,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
459,lv mass index ( g / mnmbr - nmbr ),C0053917;C0439267;C0455825;C0600653;C0918012;C1334884;C1552854;C1637833;C2986546
459,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
459,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
459,index event  %,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
459,health state index score  uk algorithm,C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231
458,prior pci or cabg surgery,C0332152;C2826257;C4049621
457,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0023779;C0168634;C0597357;C1442488
457,metabolic syndromenmbr baseline lipids  mg / dl,C0023779;C0168634;C0311400;C0439269;C1442488;C1524026;C2707259
457,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
456,mean blood pressure  mmhg ( s . d . j,C0428886;C0488053;C2347155
456,blood pressure  mean ( sd ) [range]  mm hg,C0428886;C0439475;C1514721;C2348147;C2699239;C3542016
455,> nmbr years education,C0013621;C0013622;C0013658;C0039401;C0053917;C0439234;C1334884
454,history of hypercholesterolemia,C1533076
453,severity n ( % ),C0439793;C0522510
453,acr  mg / mmol,C0567349;C1412134;C1515941;C2348885
452,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
451,years since pah diagnosis,C0439234
450,sfnmbr - pcs,C1864389;C1882368
449,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
449,creatinine  mean ( sd )  mg / dl,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
448,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
448,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
447,indacaterol nmbr ug versus placebo,C0041573;C0053917;C0439211;C1334884;C1722260
447,indacaterol nmbr ug versus indacaterol nmbr ug,C0041573;C0053917;C0439211;C1334884;C1722260
447,indacaterol nmbr ug ( n = nmbr ),C0041573;C0053917;C0439211;C1334884;C1722260
446,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
445,difference vs placebo  % [nmbr % cl]  p,C1705241;C1705242
444,sf - nmbrvnmbr domain scores  mean [sd],C0037712;C1880389;C1883221;C3541951
444,postmenopausal  never or past hormone therapy use,C0232970;C2003901
443,ischemic aetiology  n ( % ),C0015127;C0475224;C1314792;C1524003
442,prior cardiac surgery  n ( % ),C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
441,sacubitril / valsartan,C4033631
441,primary renal endpoint or death,C0022646;C2986535
441,cardiovascular history 一 no . ( % ),C1880008
440,who / idf ifg,C1334085;C1708411
439,sex  male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
439,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
438,prior diabetes,C0011847;C0011849;C0332152;C2826257
438,mean ± s . d . duration of diabetes  years,C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
438,known duration of diabetes  yr,C0011847;C0011849;C0205309;C0439234;C0449238;C2926735
438,individuals with diabetes  n = nmbr,C0011847;C0011849;C0027361;C0053917;C0237401;C1334884
438,duration of diabetes mellitus  y,C0011849;C0449238;C2926735
438,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
438,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
438,diabetes duration ( known )  % of patients,C0011847;C0011849;C0449238;C2926735
438,comorbidities other than diabetes,C0009488;C0011847;C0011849
437,ratio of ldl to hdl,C0456603;C1547037
437,p value ( men versus women ),C0025266;C1709380
437,hispanic / latin american,C0019576
436,simplified disease activity index,C3869582
435,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),C0016017;C0053917;C0205225;C0439612;C0439631;C1305868;C1334884;C4049621
435,fibrinolysis ( n = nmbr ),C0016017;C0053917;C1305868;C1334884
434,apo anmbr ( g / l ),C0439294;C0456615
433,fpg ( mmol / l )  mean ( sd ) 、,C0444504;C1532563;C2347634;C2348143;C2699239
432,peak creatine kinase - mb  u / l,C0010290;C0439339;C0444505;C0523584
432,cardiovascular risk factors — no . / total no . ( % ),C0850624
431,exenatide,C0167117
430,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
430,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
430,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
430,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
429,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
428,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
427,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
426,standard control ( n = nmbr ) no . of patients ( percent ),C0053917;C0243148;C1334884;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
426,control group ( n = nmbr ),C0053917;C0243148;C0441848;C1334884;C1550141;C1882979;C2587213;C3274648;C4553389
426,control baseline ( n - nmbr ),C0053917;C0168634;C0243148;C1334884;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
426,( % ) control ( nmbr ),C0053917;C0243148;C1334884;C1550141;C1882979;C2587213;C3274648;C4553389
425,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
425,ace - i / arb  ( % ),C0021966;C0221138;C1452534;C3888198;C4284014
424,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
424,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
424,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
423,syncope — no . ( % ),C0039070;C3541349;C4554644
423,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
422,mean ( sd ) extent of exposure  days,C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239
421,open triple ( n = nmbr ),C0175566
420,phosphorus  mmol nmbr nmbr,C0031705;C0053917;C0080014;C0439190;C1334884;C3714498
419,mean yearly decline,C0444504;C2347634;C2348143
419,fibrin - specific,C0015982
418,st change > nmbr mm,C0036056;C0053917;C0392747;C0443172;C1334884;C1705241;C3272372;C4319952;C4330985;C4554674
418,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
418,key secondary end point : st,C0036056;C3272372;C4528314
418,death  mi  idr  st  or any timi bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
417,total patients n = nmbr,C0030705;C0053917;C0439175;C0439810;C1334884
417,score > nmbr %  % of patients,C0030705;C0053917;C0449820;C1334884;C4050231
417,rate / nmbr patient - years,C0030705;C0053917;C0439234;C0871208;C1334884;C1521828
417,patients with > nmbr exacerbations resulting in hospital admission,C0030705;C0053917;C1334884;C4086268
417,all patients with fistulas ( n = nmbr ),C0016169;C0030705;C0053917;C1334884
416,lumbar spine,C0024091;C3887615
416,bare - metal stent — no . ( % ),C2825200
416,ace inhibitors or angiotensin ii blockers,C0003015
415,smoking status ( % ),C1519386
414,duration of tnmbrdm,C0449238;C2926735
413,concomitant lipid - lowering therapy  n ( % ),C0521115;C0585943
413,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
412,respiratory medication ( % ),C0418986
411,killip class,C1881332
410,qualifying event — no . ( % ),C0441471;C1514624;C4019010
410,lipid - lowering agents ( % ),C0086440
410,daily insulin dose  mean ( sd )  iu,C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501
409,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
408,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
407,pulmonary rales  n ( % ),C0034642
407,pulmonary rales,C0034642
406,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C1999375;C2346927;C4321396;C4521761
406,ticagrelor nmbr mg nmbr yr km %,C0024671;C0026410;C0053917;C0439234;C0439269;C1334884;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
406,ticagrelor  nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C1999375;C2346927;C4321396;C4521761
406,sfc nmbr / nmbr mg twice daily ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C0585361;C1334884;C1960952;C2346927;C4321396;C4521536;C4521761
406,saxagliptin nmbr . nmbr mg ( n = nmbr  nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1611934;C1960952;C2346927;C4321396;C4521761
406,rivaroxaban nmbr mg,C0024671;C0026410;C0053917;C0439269;C1334884;C1739768;C1960952;C2346927;C4321396;C4521761
406,placebo secukinumab nmbr mg,C0024671;C0026410;C0032042;C0053917;C0439269;C1334884;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
406,nmbr mg cohort,C0009247;C0024671;C0026410;C0053917;C0439269;C0599755;C1334884;C1960952;C2346927;C4321396;C4521761
406,middle tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),C0024671;C0026410;C0053917;C0439269;C0444504;C0444598;C0549183;C1334884;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
406,mepolizumab  nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C0969324;C1334884;C1960952;C2346927;C4321396;C4521761
406,indacaterol nmbr mg[n z nmbr],C0024671;C0026410;C0053917;C0439269;C1334884;C1722260;C1960952;C2346927;C4321396;C4521761
406,glycopyrronium nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C3814772;C4321396;C4521761
406,ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1532737;C1960952;C2346927;C4321396;C4521761
406,eze / simva nmbr / nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C4321396;C4521761
406,etoricoxib nmbr mg n = nmbr n ( % ),C0024671;C0026410;C0053917;C0439269;C0972314;C1334884;C1960952;C2346927;C4321396;C4521761
406,czp nmbr mg ( n nmbr nmbr ),C0024671;C0026410;C0053917;C0054841;C0439269;C1334884;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
406,czp nmbr mg  % ( n / n ),C0024671;C0026410;C0053917;C0054841;C0439269;C1334884;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
406,benralizumab nmbr mg qnmbrw ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2982078;C4321396;C4521761
406,baricitinib  nmbr mg daily ( n = nmbr ),C0024671;C0026410;C0053917;C0332173;C0439269;C1334884;C1960952;C2346927;C4044947;C4321396;C4521761
406,apremilast nmbr mg bid n = nmbr,C0024671;C0026410;C0053917;C0439269;C1334884;C1678805;C1960952;C2346927;C4321396;C4521761
406,apixaban  nmbr . nmbr mg,C0024671;C0026410;C0053917;C0439269;C1334884;C1831808;C1960952;C2346927;C4321396;C4521761
406,amlodipine / valsartan nmbr / nmbr mg / v = nmbr,C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C1962523;C2346927;C4321396;C4521761
405,western european includinq australia  israel  and south africa,C0004340;C0022271;C0043128;C0239307;C0239312;C1535514
404,carotid,C0741968
403,aspirin at any dose,C4696290
402,int . p *,C3272375
401,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
400,pancreatic cancer,C0235974;C0346647;C2984259
399,type of treatment  n ( % ),C0455708
398,angiotensin receptor blocker and / or ace,C0034787;C1622222
397,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
397,third heart sound  n ( % ),C0232237;C0232278
397,history of cardiovascular disease,C0455539
396,prior coronary revascularization  n ( % ),C0332152;C0877341;C2826257
396,oral contraceptives,C0009905
396,nadroparin vs control,C0206232
396,mean score on haq - di §,C3533236;C3826998;C4321476
396,left circumflex artery,C0226037
395,fc - ldl - c  friedewald - calculated,C2983605
394,receiving concomitant corticosteroids,C1514756
393,first - generation stentt,C0079411;C0205435;C1279901;C3146294
393,ascvd including tia,C3665365
392,no dysglycaemia or mets,C1960636
392,headache,C0018681;C4553197
392,aldosterone inhibitor,C0002007
391,time of symptom onset to balloon inflation ( hrs ),C1320528
390,alt and / or ast > nmbr times uln consecutive #,C1266129;C4553172
389,low risk and fewer symptoms ( group a ),C3272281;C3538919
389,atrial flutter,C0004239;C0344423;C1963068
388,rosiglitazone,C0289313
388,revascularization,C0581603
387,smoking status at screening  n ( % ),C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
386,intense physical activity,C0015259;C0026606;C0522510
386,exercise times per week  ( minimum,C0015259;C0456698;C1522704;C1524031;C1552614;C2826545
386,exercise,C0015259;C1522704
385,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
385,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
385,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
385,ncep risk category at study entry  n ( % ),C0035647;C1705654;C2983287;C2983669;C4552904
385,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
385,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
385,absolute risk difference ( ci )  % *,C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
384,pre - bronchodilator fevnmbr / fvc ratio *,C0456603;C1547037;C2599602;C3714541
384,post - bronchodilator fvc ( l ) a,C2599594;C3714541
384,fevnmbr / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
384,fevnmbr / fvc ( post - albuterol ),C3714541
384,fevnmbr / fvc  %  mean ( sd ) nmbr,C0053917;C0444504;C1334884;C2347634;C2348143;C2699239;C3714541
383,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
383,endoscopy subscore,C0014245
382,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
382,antithrombotic / coagulant,C0009117
381,fevi  % predicted  mean ( sd ) nmbr,C0849974;C1561566;C4528367
380,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
380,history of cardiovascular disease — no . ( % ) ^ |,C0455539
379,exacerbations,C4086268
378,risk reduction  %,C1137094
378,inflammatory disease,C1290884
377,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
377,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
377,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
377,heart failure — no . ( % ),C0018801;C0018802;C4554158
377,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
377,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
377,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
377,cardiac failure  n ( % ),C0018801;C0018802
377,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
376,rankin grade,C0441800;C0919553;C3244287
375,medical history and risk factors — no . ( % ),C0262926;C1704706
374,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
373,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
373,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
373,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
373,placebo no . / total ( % ),C0032042;C1696465;C1706408
373,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
373,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
373,placebo every nmbr weeks ( n = nmbr ),C0032042;C1696465;C1706408
373,placebo estimated mean,C0032042;C1696465;C1706408
373,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
373,placebo  n ( rate ),C0032042;C0871208;C1521828;C1696465;C1706408
373,losartan + placebo,C0032042;C0126174;C1696465;C1706408
373,feno placebo ( lsm ),C0032042;C1696465;C1706408
373,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
372,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
371,parental history of myocardial infarction before nmbr yr of age ( % ),C0030551;C1275835
370,planned treatment strategy,C0599880;C0679199
369,qualifying mi type,C0332307;C1514624;C1547052;C3810814
368,western europe hr ( nmbr % cl ),C0043129;C0053917;C0596019;C1334884
368,western europe and other,C0043129
368,western europe and israel,C0043129
367,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
367,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
367,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
366,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
365,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
364,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
363,bnp  median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
363,allhat - llt,C2347090
362,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
361,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
360,crp  mg / l : median ( range ),C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
359,pre - bronchodilator fevnmbr ( % predicted normal ),C2599602
359,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
358,other anticoagulant,C0003280;C0848112;C3536711
358,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
357,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
356,subarachnoid hemorrhage,C0038525
356,laba users,C1706077
356,aldosterone blocker  %,C0002006
355,not reported in ecrf,C1518422
354,hbanmbrc category  n ( % ),C0683312;C3889287
353,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
352,prior antihypertensive medication  n ( % ),C0003364;C0332152;C2826257
352,antihypertensive medication or,C0003364
352,antihypertensive drug  %,C0003364
352,antihypertensive  antianginal  and other cardiovascular medications,C0003364;C1874267;C3537168
351,with revascularisation,C0581603
350,patient ' s global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
349,final timi flow,C0205088;C1546485;C3272266;C3853528
349,blood eosinophils count,C0014467
349,associated with connective tissue disease,C0009782;C0332281
348,opg  ( ng / ml ),C0439275;C1262886;C1336645;C1412836;C1710303
347,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
347,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
346,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
345,mean ( s . d . ) free pcsknmbr  ng / ml,C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143
344,age  yrs  median ( nmbrth  nmbrth ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
343,diabetes therapy  n ( % ),C3274787;C3539002
342,post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239
342,leisure,C0086542
341,angiography — no . ( % ),C0002978
341,angiographic data,C0002978;C1511726;C3245479;C3714741
341,angiographic complications  site - reported — no . / total no . ( % ),C0002978;C0009566;C0205145;C1171258;C1515974;C2825164
341,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
341,> nmbr ( ml ) additional angiography,C0002978;C0053917;C0439526;C1334884;C1524062;C1705224;C3887665
340,history of systemic hypertension,C0205373;C0455527
339,mean number of exacerbations ( per patient - year [nmbr % ci] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
338,number of concomitant aeds  n ( % ),C0180309;C0237753;C0449788;C0521115
337,glucose test,C0337438;C0595310
336,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
335,nt - probnp  median ( iqr )  pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
335,change in nt - probnp at nmbr months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
334,use nmbr - asa compounds,C0004057;C0042153;C0053917;C0205198;C0457083;C1334884;C1706082;C1947944;C3853627
334,no use of nmbr - asa compounds,C0004057;C0053917;C0205198;C1334884;C1524063;C1706082;C3853627
334,aspirin only ( n = nmbr  nmbr ),C0004057;C0053917;C0205171;C1334884;C1720467
334,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0004057;C0027361;C0053917;C0439234;C0441848;C1334884;C2347489
334,aspirin - erdp ( n = nmbr  nmbr ),C0004057;C0053917;C1334884
333,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
333,endovascular — no . ( % ),C0524425
332,missing data — no . / total no . ( % ),C4684714
331,reversibility of fevnmbr ( % ),C0449261
331,cv event  years,C0439234;C0441471;C3538987;C4019010;C4048877;C4318503
330,selected clinical characteristics  n ( % ),C0683325;C1707391
329,myocardial ischaemia,C0010054;C0151744
329,ischemic heart disease  %,C0010054;C0151744
328,pdenmbr inhibitor monotherapy,C1999216
327,bronchitis,C0006277
326,sbp < nmbr mmhg and dbp < nmbr mmhg,C0053917;C0085805;C0439475;C1334884
326,change in sbp ( nmbr months ),C0053917;C0085805;C0392747;C0439231;C0443172;C1334884;C1705241;C4319952
325,classification of af  no . ( % ),C0008902;C0008903;C0344434;C0678229;C4049859
324,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
324,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
324,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
324,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
323,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
323,vascular disordersb,C0005847;C1558950;C1801960
323,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
323,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
322,ischaemic  n ( % ),C0475224
321,wrist fracture,C0435630;C4553927
320,history of myocardial infarction ( % ),C1275835
319,losmapimod,C3272847
318,use of ics,C0815320;C1524063;C4551720
318,laba / ics use at screening  n ( % ),C0815320;C4551720
318,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
318,laba + ics,C0815320;C4551720
318,ics use at screening  n ( % ),C0815320;C4551720
318,ics  mg / day,C0439422;C0815320;C4551720
317,severely impaired,C0205082
317,outcome,C1274040
316,mean — g / dl,C0439267;C0444504;C2347634;C2348143
315,smoking history — no . ( % ),C1519384
315,microvascular eye diseased,C0015392;C0443258;C0700042
315,hawaiian / pacific,C0337920
314,urinary albumin - to - creatinine ratio^,C0455271;C1318330
314,other countries,C0454664
313,mets w / o tnmbrdm,C0812270;C1705694;C2939420
312,worsening angina,C0002965
312,education  high school or higher,C0683862
311,low density lipoprotein cholesterol  mg / dl * *,C0023824;C0439269
311,low - density lipoprotein cholesterol  mg / dl,C0023824;C0439269
311,low - density lipoprotein cholesterol  %,C0023824
311,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
311,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
311,calculated ldl cholesterol ( week nmbr ),C0023824;C0053917;C0202117;C0332174;C0439230;C0444686;C1334884;C1441506
310,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
309,diuretic — no . / total no . ( % ),C0012798
309,diuretic agent,C0012798;C0450442;C1254351;C1521826
308,relative risk reduction ( nmbr % cl ),C0053917;C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1334884;C1547039;C4551656
307,other antiarrhythmics^,C0003195
307,crohn ' s disease activity index score],C0449820;C0451071;C4050231
307,ace inhibitors or angiotensin ii,C0003015
306,one or more blood pressure medications  n ( % ),C0205447
305,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
304,single vessel coronary artery disease *,C0581374
304,dipyridamole,C0012582
303,never used lev,C0023556;C1273517;C2003901
302,difference from baselinea,C1705241;C1705242
301,prior therapy with tnf antagonist  n ( % ),C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
301,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
301,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
300,not reported / unknown,C1518422
299,neoplasia  n ( % ),C0027651;C1882062
299,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
298,total cholesterol ( mg / dl )  mean + sd  available for nmbr patients,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
298,medical characteristics,C0199168;C0205476;C1521970
297,pasi score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
296,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
296,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
296,continued thienopyridine n = nmbr subjects,C0053917;C0549178;C1120149;C1334884
296,continued thienopyridine n ( % ),C0549178;C1120149
295,nasal polyps,C0027430
294,valvular disease ( % ),C3258293
294,use of parenteral antithrombotic,C0030547;C1524063;C4522267
294,philippines,C0031529
294,coumadin,C0699129
293,family history of coronary artery disease,C2317524
292,mean ( sd ) body mass index  kg / mnmbr,C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C4054209
292,body mass index > nmbr kg / mnmbr  n ( % ),C0005893;C0022718;C0053917;C0439209;C0578022;C1305855;C1334884;C4054209
292,body mass index ( kg / mnmbr ) - mean ± sd,C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C4054209
292,body mass index ( bmi )  kg / mnmbr,C0005893;C0022718;C0439209;C0578022;C1305855;C4054209
292,body mass index  median  ( nmbrth — nmbrth percentiles )  kg / mnmbr,C0005893;C0022718;C0439209;C0549183;C0578022;C0876920;C1264641;C1305855;C2347635;C2348144;C2939193;C4054209
292,body mass index  kg / mnmbr  median ( qnmbr  qnmbr ),C0005893;C0022718;C0439209;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193;C4054209
292,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
291,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
290,urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
289,incidence rate,C1708485
288,proportion of predicted normal fevnmbr value   §,C0086715;C0681842;C1709707;C1882327
288,missing data,C4684714
287,c - peptide  median ( ql  qnmbr )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
286,diet plus pravastatin group ( n = nmbr ),C0012155;C0012159;C0053917;C0085542;C0332287;C0441848;C1334884;C1519433;C2983588;C3668949
286,diet + pravastatin ( n = nmbr ),C0012155;C0012159;C0053917;C0085542;C1334884;C1519433;C2983588;C3668949
285,theophylline compound,C0039771;C0205198;C1706082
285,multiple tnfi *,C0439064
284,median serum periostin  ng / mla,C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
283,rentrop score,C0449820;C4050231
282,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
282,canakinumab,C2718773
281,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
280,odds ratio versus placebo ( nmbr % ci ),C0028873
280,odds ratio,C0028873
279,notable abnormalities,C0000768;C0000769;C4288581
278,oral anticoagulant — no . / total no . ( % ),C0354604
278,carotid stenosis,C0007282
277,multivessel pci,C4049621
276,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
275,intervention in complex lesions,C0221198;C1292781
275,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
274,severe teaes,C0205082;C4050465;C4050466
273,prior coronary revascularization,C0332152;C0877341;C2826257
273,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
272,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
272,metformin dose  mg,C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
272,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
272,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
272,concomitant atorvastatin dose  mg,C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
271,mi type unknown ( % ),C0332307;C1547052;C3810814
270,non - metsyn,C1518422
270,hematologic,C0018943;C0205488
269,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
269,permanent,C0205355
269,community hospital ( % ),C0020003
268,pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834
267,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
267,device group,C1706365
266,ezetimibe nmbr mg + statin ( n = nmbr  nmbr ),C0024671;C0026410;C0053917;C0360714;C0439269;C1142985;C1334884;C1960952;C2346927;C4321396;C4521761
265,selexipag,C2000145
265,left anterior descending,C0205386;C0441998;C1547177
265,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
264,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
264,planned valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
264,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
263,dx at presentation  n ( % ),C0449450;C3538936
262,other nsaids,C0003211
262,nsaid use — no . / total no . ( % ),C0003211;C3536840
261,yes  insulin - treated,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
261,left bundle - branch block,C0023211;C0344420;C2828132
261,current smoker : ex - smoker ( % ),C3173209;C3241966
260,heart disease risk factors,C0741920
260,angina pectoris — no . ( % ),C0002962
259,efficacy and safety : net adverse clinical events *,C1280519;C1707887
258,number of prior csdmards  n ( % ),C0237753;C0332152;C0449788;C2826257
257,iglar ( insulin glargine lnmbr u ),C0439148;C0907402
257,glargine,C0907402
257,detemir / insulin glargine  %,C0537270;C0907402
256,nmbr - h pmg ( mg / dl ),C0033727;C0053917;C0369286;C0439269;C0441932;C0564385;C1334884;C4528284
256,baseline nmbr - h ppg ,C0033727;C0053917;C0168634;C0369286;C0441932;C0564385;C1334884;C1418888;C1442488;C4528284
256,after nmbr h,C0033727;C0053917;C0369286;C0441932;C0564385;C1334884;C4528284
255,electrophysiological study — no . ( % ) weight — ibj,C0850293
254,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
254,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
254,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
254,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
254,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
253,post - bronchodilator ratio of fevnmbr to fvc — %,C0456603;C1547037;C2599594
253,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
252,receiving concomitant nsaids and / or cox - nmbr inhibitors,C1514756
252,radius fracture,C0034628
251,measurements,C0242485
250,left anterior descending  n ( % ),C0205386;C0441998;C1547177
249,use of hormone replacement therapy ( a ),C0282402;C1524063
249,steroids § §,C0038317
249,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
249,investigator - reported hypoglycaemia *,C0035173
248,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
247,n analysed,C0369718;C0441922
247,anti - inflammatory drugs,C0003209
247,ace inhibitor or arb at enrollment,C0003015;C4541021
246,history of cardiac arrhythmia,C3494593
245,p value versus placebo,C1709380
244,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
243,ratio of women to men — %,C0043210;C0456603;C1547037
242,ranolazine  n = inmbrinmbr,C0073633
242,health - related quality of life,C4279947
242,discontinuations,C0457454
242,antimalarials only,C0003374;C0205171;C1720467
241,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
241,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
241,median ( qnmbr : qnmbr ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
240,non - caucasian eze / simva ( „ = nmbr },C0007457;C0043157;C0053917;C1334884;C1518422
240,caucasian simva ( „ = nmbr },C0007457;C0043157;C0053917;C1334884
239,serum pnmbrnp ( ^g / liter ),C0229671;C0439267;C0475211;C1546774;C1550100
239,serum haemoglobin anmbrc concentration ( % )  mean ( sd ),C0019029;C0019046;C0229671;C0444504;C0683149;C1314664;C1318517;C1546774;C1550100;C2347634;C2348143;C2699239
238,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
238,metabolizer phenotype ( % ) §,C0031437;C1285572
237,secukinumab,C3179547
237,nyha class iii or iv ( n = nmbr ),C1882086
237,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
236,event rates  %,C0441471;C0871208;C1521828;C4019010
236,dyspnoea - mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
235,evaluable for acrnmbr at week nmbr  n,C1516986
234,cigarette users,C0677453;C1704760;C1706077;C3890423
234,atrial fibrillation / flutter  n ( % ),C0155709
233,> nmbr % stenosis of coronary  carotid  or lower extremity arteries,C0007282;C0018787;C0053917;C0242231;C0741968;C1334884
232,indeterminate or unknown,C0205258
231,peri - or postmenopausal,C0347985
231,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
230,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
230,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
229,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
229,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
228,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
228,egfr  ml / min / mnmbr,C0439445;C1739039;C3811844;C3812682
228,chd risk equivalents  n ( % ),C0439185;C1282512;C4049980
227,clopidogrel plus aspirin ( n = nmbr ),C0004057;C0053917;C0070166;C0332287;C1334884
227,clopidogrel ( n = nmbr ),C0053917;C0070166;C1334884
227,clopidogrel ( n = nmbr  nmbr ),C0053917;C0070166;C1334884
227,aspirin nmbr clopidogrel,C0004057;C0053917;C0070166;C1334884
227,aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,C0004057;C0053917;C0070166;C1334884
226,age when diabetes first diagnosed — yr,C0001779
225,exposure,C0274281;C0332157
225,endothelin - receptor antagonists,C1134681;C2266875
224,anti - ischaemia agents *,C0022116;C0040616;C4321499
223,mean bmi  kg / mnmbr ( s . d . ),C0444504;C0578022;C1275571;C2347634;C2348143
222,factor xa inhibitor,C2825027;C4553708
221,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
220,prior use of biologics  n ( % ),C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
220,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
220,other biologic agent,C0005515
220,biologic naive,C0005515;C0205460
220,biologic agents,C0005515
219,data missing,C1511726;C3245479;C3714741
218,three or more drugs,C0205449
218,pacific islander,C0242191
217,apolipoprotein b^,C0003593
217,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
216,pain in extremity,C0030196;C4553007
215,any event,C0441471;C4019010
214,race / ethnicity  %,C0015031;C0034510;C0243103;C1706779;C3853635
214,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
214,ethnicity ( % ),C0015031;C0243103
214,ethnic origin  n ( % ),C0015031
214,ethnic origin,C0015031
214,ethnic group — no . ( % ) ',C0015031;C1879937
213,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
212,cvd risk factors ( age > nmbr ),C0001779;C0001783;C0007222;C0035647;C0035648;C0053917;C1334884;C1553898;C4552904
211,p  all vs all,C0369773;C2603361
210,number of exacerbations in last nmbr months ,C0237753;C0449788;C4086268
210,death from any cause,C0007465
209,postmenopausal  current hormone,C0019932;C0232970;C0521116;C1705970;C4521914
209,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
208,depressed and low perceived social support,C0344315;C0549249
208,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
208,age at diagnosis  y,C1828181;C3173302
207,mean ( sd ) number of albuterol per day  puff,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
207,fevnmbr  litres ( post - salbutamol )  mean ( sd ),C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826
207,albuterol reversibility  %,C0001927;C0449261
206,oral antidiabetes monotherapya  n ( % ),C0442027;C4521986
206,digitalis,C0012252;C0304520
206,comorbid diseasesa diabetesb,C0009488
205,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
205,nicotine pack - years,C0028040;C1277691
205,mean age  y  median ( range ),C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016
205,ace inhibitor or arb at last follow - up,C0003015;C4541021
204,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
203,pulmonary disease,C0024115
203,combined estimated gfr and albuminuria status,C0205195
202,sita nmbr + pio nmbr,C0030800;C0053917;C1334884;C2347712
202,sita / pio nmbr / nmbr,C0030800;C0053917;C1334884;C2347712
201,risk factors  %,C0035648;C1553898
201,median change  %,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
200,decreased appetite,C0232462
200,ada ifg,C1060325;C1334085;C1708411;C3811629
199,liraglutide nmbr . nmbr mg ls means ( n ),C0023668;C0024671;C0026410;C0053917;C0439269;C1334884;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
198,resection performed  %,C0015252;C0728940
198,bursitis,C0006444
197,crp  nmol / l  median ( range ),C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
196,laboratory findings,C0587081
195,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
195,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
195,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
194,psoriasis duration  yrs *,C0033860;C0449238;C2926735
194,psoriasis duration  mean ± sd  years,C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
194,duration of psoriasis  years,C0033860;C0439234;C0449238;C2926735
193,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
192,oral hypoglycemic drug,C0359086
192,involved intestinal area  n ( % ),C0021853;C1879646
192,ace inhibitor monotherapy,C0003015;C4541021
191,mean pulse pressure  mmhg ( s . d . ) “,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143
190,hbanmbrc distribution,C0520511;C1704711
190,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
189,atenolol strategy,C0004147;C0679199
189,atenolol *,C0004147
188,microalbuminuria or proteinuria,C0730345
188,measured at home with automated device,C0444706;C3541902
187,lesions bnmbr / c,C0221198
187,antithrombotic agents  n ( % ),C1704311
186,aml / val nmbr / nmbr mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0053917;C0439269;C0523975;C1334884;C1960952;C2346927;C4321396;C4521761
185,atv nmbr mg study protocol,C0024671;C0026410;C0053917;C0210243;C0439269;C0674679;C1145759;C1334862;C1334884;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
184,puerperium,C0034042;C0086839;C1879329
183,week nmbr ( itt population ),C0032659;C0053917;C0332174;C0439230;C1257890;C1334884
183,safety population  n ( % ),C0032659;C0036043;C1257890;C1705187
182,visits nmbrenmbr,C0545082;C1512346
181,serum total cholesterol  mmol / l ( sd ),C0587184;C1287371;C1532563;C2699239
180,proctosigmoiditis,C0033252
180,non - stemi,C3537184
179,efficacy,C1280519;C1707887
179,anticyclic citrullinated peptide positive^  n ( % ),C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
178,triglycerides — mmol / liter,C0041004;C0439190;C0475211
178,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
178,triglycerides > nmbr mg / dl,C0041004;C0053917;C0439269;C1334884
178,triglycerides  median ( range ),C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
178,mean ± sd triglycerides  mg / dl,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
177,dose of aspirin,C4696290
176,psoriatic arthritis pain],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
175,treated with cabg — no . / total no . ( % ),C0010055;C0332293
175,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
175,history of cabg surgery  n ( % ),C0010055;C0455610
175,history of cabg surgery,C0010055;C0455610
175,coronary artery bypass surgery,C0010055
175,cabg or pci,C0010055
174,prior biologic therapy ( including anti - tnfs ),C0278947
174,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
174,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
173,tendonitis,C0039503
173,ldl - cihdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
172,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
172,atorvastatin  n ( % ),C0286651
171,serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472;C0444504;C1532563;C2347634;C2348143;C2699239
171,pulse rate ( bpm ),C0232117
170,time since diagnosis of type nmbr diabetes,C0040223;C3541383
170,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
170,time since diagnosis of diabetesa  n ( % ),C0040223;C3541383
170,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
170,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
170,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
170,time from randomization to pci ( st - elevation mi )  min,C0034656;C0040223;C3541383
170,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
170,time from acs to randomization ( median  iqr ),C0040223;C0742343;C3541383;C4318612
170,duration of ra ( time from symptom onset )  years,C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
170,cross - damp time : < l : llhrs : min ( n = nmbr ),C0040223;C0053917;C0205381;C0702093;C1334884;C1524029;C2828360;C3541383;C3813700;C3891560
169,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
169,native hawaiian or other pacific islander,C0337920
168,ez / simva n = nmbr n ( % ),C0053917;C0206578;C1334884
168,anmbr + ez n = nmbr,C0053917;C0206578;C1334884
167,atrial fibrillation / atrial flutter  %,C0155709
166,psa duration  years,C0439234;C0449238;C2926735;C3810537;C3813209
165,previous disease :,C0012634;C0205156;C1552607
165,medical conditions  no . ( % ),C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
165,left - sided disease only,C0012634;C3842976
165,disease and quality - of - life scores,C0012634
165,disease,C0012634
165,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
165,any disease,C0012634
164,nitrates ( oral or topical ),C0028125;C0699857;C3848573
164,nitrate — no . ( % ),C0028125;C0699857;C3848573
163,ischemic tvr,C0475224
162,phenytoin,C0031507;C0202454
162,former smoker  n ( % ),C0337671
161,< nmbr . nmbr mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0053917;C0456603;C0475211;C0523508;C1334884;C1532563;C1547037;C3252643;C4553344;C4553379
160,fatal and nonfatal ml,C1302234;C1705232
159,russia / georgia ( n = nmbr ),C0017452;C0017454;C0035970;C0053917;C1334884
158,ratio fp / sal : sal ( nmbr % ci ),C0008107;C0016704;C0036140;C0037494;C0053917;C0206136;C0456603;C1334884;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
157,rheumatic heart disease,C0035439
156,left atrial diameter  mm ( sd ),C0225860;C0225861;C1301886;C2699239;C4330985;C4554674
156,left atrial diameter,C0225860;C0225861;C1301886
155,steroid use at baseline  n ( % ),C0168634;C0281991;C1442488
155,steroid use at baseline,C0168634;C0281991;C1442488
155,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
155,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
155,post - bronchodilator fevnmbr  reversibility percentage of baseline value,C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594
155,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
155,mean baseline ibdq score ( sd ) § crp concentration  mg / l,C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
155,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
155,hbanmbrc distribution at baseline  n ( % ),C0168634;C0520511;C1442488;C1704711
155,hbanmbrc at baseline  %,C0168634;C1442488
155,geometric mean of baseline,C0168634;C1442488;C2986759
155,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
155,change from baseline in hbanmbrc ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
155,change from baseline in dasnmbr - esr  meannmbr sd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
155,change from baseline  adjusted mean ( nmbr % ci )  %,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
155,ccv history / condition at baseline,C0168634;C0683519;C1442488
155,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
155,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
155,baseline systolic bp,C0168634;C0871470;C1442488
155,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
155,baseline sgrq score,C0168634;C1442488
155,baseline scales  median ( range ),C0168634;C1442488
155,baseline pulmonary medication  n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
155,baseline post - bronchodilator % predicted fev  < nmbr %,C0168634;C1442488
155,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
155,baseline nihss score  median ( range ),C0168634;C1442488;C1697238
155,baseline medical therapy,C0168634;C0418981;C1442488
155,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
155,baseline mean ( sd )  % [mmol / mol],C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066
155,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
155,baseline killip class,C0168634;C1442488;C1881332
155,baseline ics use  n ( % ),C0168634;C0815320;C1442488;C4551720
155,baseline hematocrit  median ( iqr ),C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
155,baseline fpg ,C0168634;C1442488
155,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
155,baseline ecrcl,C0168634;C1442488
155,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
155,baseline diabetes,C0011847;C0011849;C0168634;C1442488
155,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
155,baseline cardiovascular medication  c n ( % ),C0007220;C0168634;C1442488
155,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
155,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
155,baseline / concomitant therapies,C0168634;C1442488;C1707479
155,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
155,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
154,location of crohn ' s disease  %,C0010346;C0450429;C1515974;C4284930;C4284931
154,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
154,crohn ’ s disease related surgery,C0010346
154,crohn ' s disease - related medication at baseline  n ( % ),C0010346
154,crohn ' s disease,C0010346
153,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
153,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
153,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
153,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
153,ezetimibe use,C0042153;C0457083;C1142985;C1947944
153,concomitant mtx use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
153,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
152,european trial,C0008976;C0239307;C1535514
152,combined trials,C0008976;C0205195
151,intravenous vasodilators ( % ),C0443081
150,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
149,no antidiabetic drug,C0935929
149,antidiabetic medication | |,C0935929
148,fevnmbr percent predicted ( sd ),C0439165
147,severity of hypertensionb,C0439793;C0522510
147,intravenous dobutamine,C0012963;C0348016
147,insulin + oad,C0021641;C1533581;C1579433;C3714501
147,coronary angiography and intervention,C0085532;C1548829
146,never / rarely,C0522498;C2003901
145,large mi,C0549177;C3810814
144,number of ( % ) females,C0086287;C0237753;C0449788
144,family history of diabetes — no . ( % ),C1313937
143,nmbr mg clopidogrel load,C0024671;C0026410;C0053917;C0070166;C0439269;C1334884;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
143,intended clopidogrel dose nmbr mg,C0024671;C0026410;C0053917;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1334884;C1551357;C1960952;C2346927;C4321396;C4521761
142,v alsartan / hctz  n ( % ),C0020261
142,hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients .,C0020261
141,number ( % ) of patients with event,C2360800
140,baseline dyspnea index  mean total score,C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236
139,severity of the disease ( gold nmbr )  n ( % ),C0018026;C0053917;C0521117;C1304897;C1334884
139,severity of copd  ( gold nmbr )  %,C0018026;C0024117;C0053917;C0439793;C0522510;C1304897;C1334884;C1412502;C3714496
139,severity of airflow limitation ( gold nmbr - nmbr )  n ( % ),C0018026;C0053917;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897;C1334884
139,severe ( gold nmbr ),C0018026;C0053917;C0205082;C1304897;C1334884;C4050465;C4050466
139,moderate ( gold nmbr ),C0018026;C0053917;C0205081;C1304897;C1334884;C1881878;C4049705;C4049706;C4085643;C4321335
139,gold nmbr groups  n ( % ),C0018026;C0053917;C1304897;C1334884
139,gold nmbr groups,C0018026;C0053917;C1304897;C1334884
138,smoking habit  n ( % ),C4505437
138,acpa positive  %,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
137,oral medications,C0304289
137,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
137,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
136,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
136,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
136,stent length per lesion  mm,C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
136,number of stents implanted,C0038257;C0237753;C0449788
136,minimum stent diameter,C0038257;C4054490
136,indication for stent,C0038257;C0392360;C3146298
135,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
135,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
134,lev status  n ( % ),C0023556;C0449438
133,dihydropyridine,C0012315;C0220821
132,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
132,chd + cerebral infarction,C0007785;C0280604;C3542407
132,age ( years ) [median ( nmbrth to nmbrth percentile ) ],C0549183;C0876920;C1264641;C1510829;C2347635;C2348144;C2939193
131,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
130,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
129,orthostatic hypotension,C0020651
129,obesity  % *,C0028754;C1963185
129,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
129,established,C0443211;C1272684
128,intraperitoneal,C0442120
128,coenzyme qnmbr  ^g / ml #,C0009235;C1300565
128,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
127,> nmbrmg / dl chd status,C0280604;C0449438;C3542407;C3642216
126,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
125,severe dysfunction,C3274777
124,negative,C0205160;C1513916;C2825415;C2825491;C3853545
123,implantable cardioverter - defibrillator,C0162589;C2825184
123,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
122,radial access,C0442038;C0444454;C0920847;C1554204
121,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
121,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
120,time to admission  min,C0702093;C1524029;C3813700;C3854258;C3854259
120,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
120,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
120,anti - ccp antibody positive,C0741132;C4318437
119,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
119,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
119,duration of morning,C0332170;C0449238;C2926735
119,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
118,positive,C0439178;C1446409;C1514241;C2825490;C3812269
117,normal ( egfr > nmbr ),C0053917;C0205307;C0231683;C0439166;C1334884;C1739039;C2347086;C3811844;C3812682;C4553972
117,egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),C0053917;C0439445;C1334884;C1739039;C3811844;C3812682
117,egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr  nmbr ),C0053917;C0439445;C1334884;C1739039;C3811844;C3812682
117,egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),C0053917;C0439445;C1334884;C1739039;C3811844;C3812682;C3839656
117,egfr < nmbr  n ( % ),C0053917;C1334884;C1739039;C3811844;C3812682
117,egfr ( mumin / nmbr . nmbr mnmbr ),C0053917;C1334884;C1739039;C3811844;C3812682
117,egfr  ml min nmbr nmbr . nmbr m nmbr,C0053917;C0369637;C0439445;C0441923;C1334884;C1739039;C3811844;C3812682
117,> nmbr to < nmbr egfr  ml / min / nmbr . nmbr mnmbr a,C0053917;C0439445;C1334884;C1739039;C3811844;C3812682
116,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
116,hispanic,C0086409
115,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
114,diabetes mellitus status,C1317301
113,pancolitis,C0868908
112,other oral hypoglycemic drug ( s ),C0359086
111,mean duration of disease  years,C0439234;C0444504;C0872146;C2347634;C2348143
111,hospitalized for asthma  n ( % ) *,C0004096;C0701159;C2984299
110,physician ' s judgment that vka,C0022423;C0031831;C0804815
109,years  mean ( sd ),C0439234;C0444504;C2347634;C2348143;C2699239
109,duration of disease  median,C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
108,patent foramen ovale,C0016522;C0344724
107,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
106,smoking history ( ever ),C1519384;C3887636
105,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
105,serious ae,C0205404;C3887670
105,left ventricular ef  mean ( sd )  %,C0225897;C0444504;C2347634;C2348143;C2699239
104,urgent coronary revascularization,C0439609;C0877341;C3272275
103,uric acid ( mg / dl ),C0041980;C0439269
103,extent of disease  %,C0449279;C4553144
102,digital clubbing  n ( % ),C0009080;C0149651
101,fevnmbr reversibilityz ( pre / post ipratropium )  %,C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034
101,family history ol diabetes ?,C1313937
100,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
99,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
99,current smoker — no . of patients ( % ),C3173209;C3241966
99,acute rheumatic disorders,C0001314
98,gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),C0017654;C0053917;C0439445;C1334884;C1424601;C3839656
98,estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,C0017654;C0053917;C0439445;C0750572;C1334884;C1424601
98,estimated gfr  ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a,C0017654;C0053917;C0369637;C0439445;C0441923;C0750572;C1334884;C1424601;C2699239
98,estimated gfr  < nmbr ml min - nmbr nmbr . nmbr m - nmbr  n ( % ) a,C0017654;C0053917;C0369637;C0439445;C0441923;C0750572;C1334884;C1424601
97,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
97,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
96,family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
96,cad and abi < nmbr - nmbr §,C1504769;C2239547;C3813548;C4284121
95,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
95,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
95,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
94,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
94,statin with niacin,C0027996;C0360714;C1142562
94,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
94,statin potency stratum  n ( % ),C0360714;C3245505
94,statin monotherapy,C0360714
94,statin + ezetimibe  n ( % ),C0360714;C1142985
94,statin ( open ),C0360714
94,other statin,C0360714
94,no statin vs statin alone vs any statin plus other llt,C0360714
94,neither pbo + statin eze + statin,C0031962;C0360714
94,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
94,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
94,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
94,baseline statin usec,C0168634;C0360714;C0439224;C1442488
94,any statin + other llt,C0360714
93,thoracic cage fractures,C0222762
93,diskus only  n,C0205171;C1553480;C1720467
92,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
92,smoking pack - years,C0037369;C0453996;C1277691;C1881674
92,smoking in the past year,C0037369;C0453996;C1881674;C4086728
92,smoking : ex - smoker,C0037369;C0453996;C1881674
92,smoking ( a ),C0037369;C0453996;C1881674
92,mean ( sd ) duration of smoking  pack years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
91,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
91,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
91,cardiovascular hospitalization,C0007226;C0019993;C3887460
91,cardiovascular and respiratory,C0007226;C3887460
91,all cardiovascular,C0007226;C3887460
90,triple therapy use at screening  n ( % ),C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434
90,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
90,treatment difference  ml,C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704
90,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
90,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
90,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
90,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
90,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
90,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
90,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
90,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
90,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
90,previous copd treatment  n ( % ) *,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
90,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
90,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
90,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
90,inadequate response / intolerance to prior therapy  %,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
90,icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0021122;C0039798;C0087111;C1363945
90,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
90,antithrombotic therapy,C0039798;C0087111;C1363945
90,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
90,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
89,normal fasting glucose level ( n = nmbr ),C0015663;C0053917;C0202045;C0205307;C0231683;C0439166;C0522082;C1334884;C2347086;C4553972
89,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
89,fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
89,fasting glucose  mmol / l  mean ± sd,C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239
89,fasting free fatty acids ( ^mol / liter ),C0015663
89,fasting c - peptide  ng / ml,C0006558;C0015663;C0439275
89,fastest third,C0015663;C0205437;C0456962;C2985769
88,history of hyperlipidemia ( % ),C4695788
87,median ( qnmbr : qnmbr ) duration of insulin use  years,C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
87,cognitive functioning,C0392334;C0392335
86,beta - blockers ( all )  n ( % ),C0001645
86,beta - blocker — no . ( % ),C0001645
86,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
86,beta - blocker ( except sotalol ),C0001645;C0037707
86,beta - adrenergic blocker,C0001645;C2757061;C3536830
85,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
84,tiotropium nmbr gg qd,C0017454;C0018370;C0053917;C0213771;C0332173;C1334884
84,salmeterol nmbr gg bid,C0017454;C0018370;C0053917;C0073992;C1334884
84,indacaterol nmbr gg qd,C0017454;C0018370;C0053917;C0332173;C1334884;C1722260
84,ind nmbr gg q . d . n / n ( % ),C0017454;C0018370;C0053917;C1334884;C4049864
84,gly nmbr . nmbr gg b . i . d n / n ( % ),C0017454;C0018370;C0053917;C0152277;C1334884;C1415124
84,formoterol nmbr gg bid,C0017454;C0018370;C0053917;C0060657;C1334884
84,ff / vi nmbr / nmbr gg ( n = nmbr  nmbr ),C0017454;C0018370;C0053917;C0205999;C1334884;C4554348
83,previous dmards use  n ( % ),C0205156;C0242708;C1552607
83,dmard | |,C0242708
83,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
82,tocilizumab,C1609165
82,oxidative stress,C0242606
82,dactylitis count,C0239161;C0750480;C1705566
81,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
81,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
81,atrial fibrillation  n ( % ),C0004238;C0344434;C1963067
81,atrial fibrillation  duration — no . ( % ),C0004238;C0344434;C0449238;C1963067;C2926735
80,total updrs score ( range  nmbr - nmbr ) 卞,C0439175;C0439810;C3639721
80,secondary ( change in total updrs score from baseline to final visit in phase nmbr ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
79,cv medication  % of patients,C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503
78,risk of bleeding,C3251812
78,repaired chd,C0205340;C0280604;C3542407
77,mean ± sd waist circumference  cm,C0444504;C0455829;C2347634;C2348143;C2699239
77,increased waist circumference,C0205217;C0442805;C0455829
76,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
76,glyburide,C0017628
75,ptca or pci,C2936173
75,both ptca and cabg,C2936173
74,prior myocardial infarction,C0155668
74,no . of risk factors ( % ) | |,C0035648;C1553898
73,homa . % b  median ( ql  qnmbr )  %,C0549183;C0876920;C2347635;C2348144;C2939193
73,cangrelor  %,C1121991
72,muscle spasms,C0037763
72,health habits,C0679786
71,right coronary,C0225808
70,native hawaiian / other,C0337920
70,lp ( a )  mean ( sd ),C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
70,diabetic treatments !,C0087111;C0241863
70,bypass surgery,C1536078
70,any immunosuppressive agent,C0021081
69,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
69,crude analysis  n ( % ),C0002778;C0936012;C1524024
68,draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177
67,lvdd ( mm ),C4330985;C4554674
66,primary end point  no . of events / total no . ( % ),C2986535
65,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
65,peripheral arterial disease  n ( % ),C0085096;C1704436
65,any peripheral arterial disease,C0085096;C1704436
64,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
63,mean prebronchodilator fevnmbr ( sd )  % predicted,C0444504;C2347634;C2348143;C2599602;C2699239
63,ctn - l  ng / ml,C0439275;C0917591
62,no . of prior bdmards,C0332152;C2826257
61,no p - blocker intake at randomisation ( n = nmbr ),C0034656;C0053917;C0369773;C1334884;C1512806;C2603361
61,coronary revascularization nmbr days after randomization,C0034656;C0053917;C0439228;C0877341;C1334884
60,haemorrhagic,C0333275
59,years since menopause,C0439234
58,concomitant corticosteroid use  n ( % ),C0239126;C0521115
57,type of mi ( % ),C0332307;C1547052;C3810814
57,arthritis,C0003864;C4552845
56,atenolol n = nmbr no . ( % ),C0004147;C0053917;C1334884
56,atenolol n = nmbr,C0004147;C0053917;C1334884
56,atenolol ( « = nmbr nmbr ),C0004147;C0053917;C1334884
55,ccbs  ( % ),C0006684
55,calcium channel blockers  n ( % ),C0006684;C2757014
55,calcium channel antagonists  n ( % ),C0006684;C2757014
55,calcium antagonists  n ( % ),C0006684
55,calcium - channel blockers ( % ),C0006684;C2757014
55,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
54,total chol  mg / dl,C0201950;C0439175;C0439269;C0439810
54,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
54,hbanmbrc  mean ( sd )  % [mmol / mol],C0444504;C2347634;C2348143;C2699239;C3829066
53,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
53,absolute  litres,C0205344;C0475211
52,gemfibrozil,C0017245
52,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
52,dasnmbr ( esr )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3811131
52,cardiac resynchronization therapy,C1167956
51,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
50,bare metal stent  n ( % ),C2825200
49,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
48,mean nmbrmwd *  m ( sd ),C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
47,ezetimibe,C1142985
47,after bronchodilation,C1371299;C3537072
46,with placebo ( n nmbr nmbr ),C0032042;C0053917;C1334884;C1696465;C1706408
46,rerandomization to placebo ( n = nmbr ) f,C0016327;C0032042;C0053917;C1334884;C1696465;C1706408
46,placebo nmbr year km ( % ),C0032042;C0053917;C0439234;C0439508;C1334884;C1696465;C1706408;C3887676
46,placebo n = nmbr subjects,C0032042;C0053917;C1334884;C1696465;C1706408
46,placebo event rate ( n = nmbr )  %,C0032042;C0053917;C0441471;C0871208;C1334884;C1521828;C1696465;C1706408;C4019010
46,nmbr placebo n = nmbr,C0032042;C0053917;C1334884;C1696465;C1706408
46,n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),C0032042;C0053917;C0369718;C0441922;C1319635;C1334884;C1696465;C1706408;C1722260
46,difference ( tiotropium - placebo ) ml ( nmbr % ci ),C0008107;C0032042;C0053917;C0213771;C0439526;C1334884;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
45,cardiovascular history,C1880008
44,ntpro - cnp ( ng / ml ),C0439275;C3889729
43,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
43,acute coronary event,C0205178;C0741923
43,abdominal or perianal fistula at baseline  n ( % ),C0000726
43,abdominal aortic — no . ( % ),C0003484
42,american indian or native alaskan,C0002460
42,american indian or alaska,C0002460
41,pasi score ! * *,C0449820;C4050231;C4528685
40,other asian,C0078988
40,estimated glomerular filtration,C0232809;C0750572
39,invasive,C0205281;C1334278
38,neoplasia,C0027651;C1882062
38,hbanmbrca  % ( mmol / mol ),C3829066
37,prior years taking warfarin,C0332152;C0439234;C2826257
36,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
36,prior lipid - modifying therapy,C0023779;C0392747;C1514463
36,other lipid parameters,C0023779;C0449381
36,mean lipid values  mg / dl,C0023779;C0042295;C0439269;C0444504;C2347634;C2348143
36,lipid profile,C0023779;C1979963;C2003903
36,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
36,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
35,median total cholesterol  mmol / l,C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
35,diltiazem or verapamil,C0012373
34,seizure types reported during baseline  n ( % ) a,C0036572;C0332307;C1959629;C4553401
34,age at first seizure  years  mean ( sd ),C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401
33,normoalbuminuria at baseline ( nmbr % of patients treated ),C0030705;C0053917;C0168634;C1334884;C1442488
33,crcl at baseline < nmbr ml / min,C0053917;C0168634;C0439445;C1334884;C1442488;C1846718
33,baseline lp ( a ) in nmbr classes,C0053917;C0065058;C0168634;C0456387;C1334884;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
33,baseline hb < nmbr g nmbr nmbr n = nmbr,C0053917;C0062408;C0168634;C0439267;C1334884;C1442488
33,baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr,C0022718;C0053917;C0168634;C0439209;C0578022;C1334884;C1442488;C4054209
33,baseline albumin / creatinine ratio in nmbr classes,C0053917;C0168634;C0456387;C0486293;C1318293;C1334884;C1442488;C1518526;C1705943;C4019422
33,baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,C0053917;C0168634;C0439375;C1334884;C1442488;C1623465;C1861303
33,adjusted mean change from baseline ( nmbr % ci )  % [mmol / mol],C0008107;C0053917;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1334884;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952
32,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
31,trend / het . test,C1521798;C4554533
31,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
30,ppi use ( p = nmbr - nmbrt ),C0358591;C0871125;C3811894
30,ppi but no aspirin,C0358591;C0871125;C3811894
30,nontrial ppi,C0358591;C0871125;C3811894
30,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
29,mean a ± sem ( % ),C0444504;C2347634;C2348143
29,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
28,after pci,C4049621
27,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
27,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
27,cv death  ml  or stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
26,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
26,pooled simva,C1709595;C2349200;C4522255
25,st - elevation mi,C0520886;C3810814
25,serum albumin  g / dl,C0036773;C0439267;C0728877
24,fatigue,C0015672;C3463815;C4050243;C4554645
24,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
23,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
22,single - vessel disease  n ( % ),C0037179;C0042373;C0087136;C0205171
21,left ventricular ejection fraction  % af history,C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859
21,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
21,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
21,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
21,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
21,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
21,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
21,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
21,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
21,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
21,cardiac history  %,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
21,cad history and risk factors  n ( % ),C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
21,baseline copd exacerbation history  * n ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
20,weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0022718;C0439209;C0549183;C0552346;C0876920;C2347635;C2348144;C2939193;C4054209
20,weight  median ( nmbrth — nmbrth percentiles )  kg,C0022718;C0439209;C0549183;C0552346;C0876920;C2347635;C2348144;C2939193;C4054209
20,mean ± sd bmi  kg / mnmbr,C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C4054209
20,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
20,body mass  kg,C0022718;C0439209;C0518010;C4054209
20,bmi ( kg / mnmbr ) cardiac parameters,C0018787;C0022718;C0439209;C0449381;C0578022;C1522601;C4054209
20,bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2923536;C2939193;C4054209
19,non - q wave,C0429089;C1305738;C1518422
19,neuropilin ( ng / ml ),C0287275;C0439275
19,ace inhibitor — no . ( % ),C0003015;C4541021
18,lesion length  mean ( sd )  mm,C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
18,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
17,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
17,mtx + non - mtx,C0025677;C1417487;C1518422
17,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
17,concomitant mtx —,C0025677;C0521115;C1417487
16,number of patients with,C2360800
15,vents / patients,C0030705
15,total comparators  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390
15,subset of patients on metformin,C0030705;C1515021
15,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
15,patients without ra  as  or psa ( n = nmbr  nmbr ),C0030705;C3538806;C4048756
15,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
15,patients with diabetic nephropathy,C0011881;C0030705;C1442864
15,patients treated with insulin,C0030705
15,patients treated for > nmbr weeks ( % ),C0030705
15,patients receiving corticosteroids at baseline,C0030705
15,patients not receiving corticosteroids at baseline,C0030705
15,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
15,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
15,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
15,no . of patients / total no . ( % ),C0030705
15,hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se ),C0030705
15,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
14,argentina,C0003761;C1504311
13,emphysema ( % ),C0013990;C0034067
12,timi major / minor,C4441842
12,nmbrth - nmbrth percentiles,C1264641
12,hba  % nmbrc,C0019016;C1825777;C3538758
12,current tobacco abuse  n ( % ),C0040336;C0521116;C1705970
11,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
11,three arm,C0205449;C0446516;C3715044;C4553528
11,paracetamol,C0000970
11,medication adherence,C2364172
11,acute stent thrombosis,C0205178;C3897493
10,total invasive cancer,C0439175;C0439810;C0677898
9,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
8,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
8,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
8,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
8,previous medications  n ( % ),C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
8,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
8,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
8,other drugs,C0013227;C3687832
8,number of antidiabetes drugs at screening  n ( % ),C0013227;C0237753;C0449788;C3687832
8,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
8,medication use — no . ( % ),C0013227;C3244316;C4284232
8,medication taken alone or in combination,C0013227;C3244316;C4284232
8,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
8,glycemic drugs,C0005802;C0013227;C3687832
8,drugs used in diabetes  n ( % ),C0013227;C3687832
8,drug - related teaesnmbr,C0013227;C0439849;C0445223;C1254351
8,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
8,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
8,concomitant drugs,C0013227;C0521115;C3687832
8,concomitant antihyperglycaemic drugs  n ( % ),C0013227;C0020616;C0521115;C3687832
8,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
7,p  subgroup *,C0369773;C1079230;C1515021;C2603361
7,median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
6,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
6,treatmentofpulmonary embolismpriorto randomization,C0034656
6,randomized to receive beta carotene,C0034656;C3815594
6,randomized,C0034656;C3815594
6,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
6,randomization groups nmbr and nmbr,C0034656
6,randomization - to -,C0034656
6,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
6,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
6,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
6,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
6,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
6,length of stay ( randomization to discharge  h ),C0023303;C0034656
6,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
6,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
6,asastoppedat randomization  n,C0034656
6,age at randomization ( years ),C0034656;C1510829
6,active cancer at randomization  n ( % ),C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
5,prior percutaneous coronary intervention  n ( % ),C0332152;C1532338;C2826257
5,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
5,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338
5,percutaneous coronary intervention,C1532338
4,high intensity,C4081854
3,terol  hdl - c  high - density lipoprotein cholesterol ,C0023822
3,high density lipoprotein cholesterol  mg / dl^,C0023822;C0439269
3,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
3,high - density lipoprotein cholesterol  mg / l,C0023822;C0439268
3,hdl cholesterol ( week nmbr ) a,C0023822;C0053917;C0332174;C0392885;C0439230;C1334884
3,> nmbr . nmbr hdl cholesterol level,C0023822;C0053917;C0201950;C0392885;C0428466;C0441889;C0456079;C1334884;C1547707;C2946261;C3715113
2,tofacitinib nmbr mg two times a day,C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
2,tofacitinib nmbr mg twice daily n = nmbr,C0024671;C0026410;C0053917;C0439269;C0585361;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
2,tofacitinib nmbr mg bid [n = nmbr |,C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
2,tofacitinib  nmbr mg ( n = nmbr ),C0024671;C0026410;C0053917;C0439269;C1334884;C1960952;C2346927;C2930696;C4321396;C4521761
1,≥ nmbr . nmbr to < nmbr . nmbr years,C0053917;C0439234;C1334884
1,weight $ nmbr . nmbr kg  < nmbr . nmbr kg  n,C0005910;C0043100;C0053917;C1305866;C1319635;C1334884;C1705104
1,week nmbr mean 士 sd,C0053917;C0332174;C0439230;C0444504;C1334884;C2347634;C2348143;C2699239
1,week nmbr fpg  mean ( s . e . ),C0053917;C0332174;C0439230;C0444504;C1334884;C2347634;C2348143
1,vorapaxar n = nmbr,C0053917;C1334884;C2974521
1,visit nmbr ldl cholesterol strata,C0023824;C0053917;C0202117;C0545082;C1334884;C1512346;C2826704
1,very severe n z nmbr,C0053917;C1334884;C3641272;C4050419
1,verapamil sr n = nmbr no . ( % ),C0053917;C1334884;C1527129
1,verapamil sr n = nmbr,C0053917;C1334884;C1527129
1,varespladib ( n = nmbr ),C0053917;C1334884;C2713485
1,upper respiratory tract infection nmbr ( nmbr . nmbr ),C0041912;C0053917;C1334884
1,uacr ( mgg - nmbr ),C0053917;C1334884
1,type nmbr diabetes 一 no . ( % ),C0053917;C1320657;C1334884
1,type nmbr diabetes mellitus ’,C0053917;C1320657;C1334884
1,type nmbr diabetes duration  years,C0053917;C0439234;C0449238;C1320657;C1334884;C2926735
1,type nmbr diabetes duration  mean ( sd )  years,C0053917;C0439234;C0444504;C0449238;C1320657;C1334884;C2347634;C2348143;C2699239;C2926735
1,type nmbr diabetes,C0053917;C1320657;C1334884
1,triglycerides ( week nmbr ) a,C0041004;C0053917;C0332174;C0439230;C1334884
1,total study population ( n = nmbr  nmbr ),C0053917;C0439175;C0439810;C0557651;C1334884;C2348561;C2603343;C3258257
1,total n = nmbr n ( % ),C0053917;C0439175;C0439810;C1334884
1,total haq  nmbr - nmbr,C0053917;C0102923;C0439175;C0439810;C0451208;C1334884
1,total group ( n = nmbr ),C0053917;C0439175;C0439810;C0441848;C1334884
1,total cholesterol ( week nmbr ),C0053917;C0201950;C0332174;C0439230;C0543421;C1334884
1,tocilizumab ( n = nmbr ),C0053917;C1334884;C1609165
1,tnl ultrapositive > nmbr . nmbr pg / l  nmbr = nmbr,C0053917;C0439278;C1334884;C1540071
1,tirofiban ( n = nmbr ),C0053917;C0247025;C1334884
1,tim nmbr nsk score,C0053917;C0449820;C1313407;C1334884;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
1,ticlopidine ( n = nmbr ),C0040207;C0053917;C1334884
1,tg < nmbr  hdl > nmbr ( n = nmbr ),C0053917;C0337445;C1334884;C3715113
1,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,C0053917;C0439297;C1334884
1,tertile nmbr,C0053917;C1334884
1,tender joint count ( nmbr - nmbr ),C0053917;C0451530;C1334884
1,tender joint count  of nmbr,C0053917;C0451530;C1334884
1,telmisartan ( n = nmbr  nmbr ),C0053917;C0248719;C1334884
1,systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),C0053917;C0439475;C0488055;C0871470;C1306620;C1334884;C1704675
1,supine after nmbr minutes change from baseline,C0038846;C0053917;C0439232;C0700321;C0702093;C1282918;C1334884;C2347166
1,standard care ( n = nmbr ),C0053917;C1334884;C1442989;C1947933;C2828392
1,standard ( n = nmbr ),C0053917;C1334884;C1442989;C2828392
1,st - segment depression > nmbr . nmbr mv on admission  %,C0053917;C0520887;C1334884;C1454484;C1705503;C4281602
1,spironolactone ( n = nmbr ),C0037982;C0053917;C1334884
1,simvastatin monotherapy ( n = nmbr  nmbr * ),C0053917;C0074554;C1334884
1,simva n = nmbr n ( % ),C0053917;C1334884
1,shs  mean nmbr sd,C0053917;C0444504;C1334884;C2347634;C2348143;C2699239
1,sglt - nmbr inhibitors^,C0053917;C1334884;C3665045
1,sfc nmbr / nmbr | ig bid n = nmbr,C0021027;C0053917;C0305052;C0360506;C1334884;C4521536
1,severe n z nmbr,C0053917;C0205082;C1334884;C4050465;C4050466
1,severe impairment ( < nmbr ),C0053917;C0205082;C0221099;C0684336;C1334884;C4050465;C4050466
1,serum creatinine > nmbr pmol / l . n ( % ) |,C0053917;C0201976;C0439284;C0600061;C1334884
1,serum creatinine > nmbr mmol / l  n ( % ),C0053917;C0201976;C0600061;C1334884;C1532563
1,serum creatinine  limo nmbr nmbr,C0053917;C0201976;C0600061;C1334884
1,serum albumin  g nmbr nmbr,C0036773;C0053917;C0439267;C0728877;C1334884
1,selexipag ( n = nmbr ),C0053917;C1334884;C2000145
1,score of > nmbr . nmbr — %,C0053917;C0449820;C1334884;C4050231
1,score distribution : < nmbr,C0053917;C0449820;C0520511;C1334884;C1704711;C4050231
1,saxagliptin nmbrmg ( n z nmbr ),C0053917;C1334884;C1611934
1,rosuvastatin n = nmbr,C0053917;C0965129;C1334884
1,rosuvastain + fenofibric acid nmbr = nmbr,C0053917;C0060179;C1334884
1,rivastigmine ( n = nmbr ),C0053917;C0649350;C1334884
1,riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),C0053917;C0683610;C1334884;C4553947
1,reversibility ( bnmbr - agonist )  %  mean ( sd ) nmbr,C0053917;C0444504;C0449261;C1334884;C2347634;C2348143;C2699239;C2987634
1,relative decrease > nmbr %,C0053917;C0080103;C0205345;C0392756;C0547047;C1334884;C1547039
1,recent cardioversion ( within nmbr days before randomization ) —,C0013778;C0053917;C0332185;C0439228;C1334884
1,ratet ( nmbr % cl ),C0053917;C0596019;C1334884
1,rasagiline  nmbr mg / day,C0053917;C0439422;C0525678;C1334884
1,ranolazine ( n = nmbr  nmbr ),C0053917;C0073633;C1334884
1,py = nmbr . nmbr ),C0030428;C0053917;C1334884;C3538810
1,psoriasis covering > nmbr % bsa  n ( % ) §,C0033860;C0053917;C0180153;C0439844;C1334884
1,psoriasis body surface area > nmbr %,C0005902;C0033860;C0053917;C1334884
1,primary pci ( n = nmbr ),C0053917;C0205225;C0439612;C0439631;C1334884;C4049621
1,presence of honeycombing  nmbr n ( % ),C0053917;C0150312;C0332468;C0349384;C0392148;C1334884;C3854307
1,pooled empagliflozin ( n = nmbr ),C0053917;C1334884;C1709595;C2349200;C3490348;C4522255
1,physical function ( nmbr - nmbr  short form - nmbr subscale ),C0031843;C0053917;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1334884;C1522492;C1705273;C1806781;C2350002;C4049916;C4255237
1,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),C0031676;C0053917;C0202177;C0441889;C1334884;C1719844
1,pfo closure group ( n = nmbr ),C0053917;C0185003;C0441848;C1334884;C1521802
1,percentage with disease duration < nmbr years,C0053917;C0439165;C0439234;C0872146;C1334884;C1549488;C1561533
1,percentage difference ( nmbr % cl ),C0053917;C0439165;C0596019;C1334884;C1549488;C1561533;C1705241;C1705242
1,pasi < nmbr *,C0053917;C1334884;C4528685
1,pain ( nmbr - nmbr mm vas ),C0042815;C0053917;C1334884;C4330985;C4554674
1,p - val . ( nmbr ),C0042285;C0053917;C0369773;C0523975;C1334884;C2603361
1,other ( nmbr . nmbr % ) t,C0053917;C1334884
1,nyha class nmbr - nmbr : no { n = llll ),C0053917;C1334884;C1882083
1,number of stent = nmbr,C0038257;C0053917;C0237753;C0449788;C1334884
1,north america n z nmbr,C0028405;C0053917;C1334884
1,north america hr ( nmbr % cl ),C0028405;C0053917;C0596019;C1334884
1,non - smoker ( n = nmbr  nmbr ),C0053917;C0337672;C0425293;C1334884;C4554605
1,non - hdl - c in nmbr classes,C0053917;C0456387;C1334884;C1518422;C1518526;C1705943;C3715113;C4019422
1,no peripheral revascularization ( n = nmbr  nmbr ),C0053917;C0205100;C0581603;C1334884
1,no . of nmbr - mg acetaminophen tablets / day,C0053917;C0439422;C1243102;C1334884
1,nmbrnd > nmbr . nmbr / < nmbr . nmbr,C0053917;C1334884
1,nmbrmwd decrease > nmbr m,C0053917;C0369637;C0392756;C0441923;C0547047;C1334884
1,nmbr yr km % ( n ),C0053917;C0439234;C1334884;C3887676
1,nmbr year or more,C0053917;C0439234;C0439508;C1334884
1,nmbr to < nmbr . nmbr %,C0053917;C1334884
1,nmbr prolonged antithrombotic pretreatment ( n = nmbr ),C0053917;C1334884
1,nmbr no . of events,C0053917;C1334884
1,nmbr mg / kg ( n = nmbr ),C0053917;C0439272;C1334884
1,nmbr locf ),C0053917;C1334884;C2825507
1,nmbr degree of ica stenosis 丰,C0053917;C0201519;C1334884;C4034225
1,nmbr bmi  kg / m,C0053917;C0578022;C1334884;C1532718
1,nmbr = minor symptoms  no limitations,C0026193;C0053917;C0205165;C0683368;C1334884;C1457887
1,nmbr = help needed  still independent,C0053917;C1334884
1,nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C0439445;C1334884
1,nmbr - nmbr / week,C0053917;C0332174;C0439230;C1334884
1,nmbr - nmbr ( severe ),C0053917;C1334884
1,nmbr - nmbr ( n = nmbr  nmbr ),C0053917;C1334884
1,nmbr - h plasma glucose during ogtt ( mmol / l ),C0029161;C0053917;C0202042;C0455280;C1334884;C2827804
1,nmbr - aminosalicylic compounds — no . ( % ),C0053917;C0205198;C1334884;C1706082
1,nmbr - aminosalicylates | | | |,C0053917;C0368663;C1334884
1,nmbr ( fevnmbr < nmbr % pred ),C0053917;C1334884
1,nmbr % < hbanmbrc < = nmbr %,C0053917;C1334884
1,nmbr  nmbr / nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884
1,myocardial infarction within the previous nmbr yr,C0027051;C0053917;C0205156;C0428953;C0439234;C1334884;C1552607;C2926063;C3810814;C4552959
1,mri substudy ( n = nmbr ),C0024485;C0053917;C1334884;C1824234;C3890166
1,montelukast ( n = nmbr ),C0053917;C0298130;C1334884
1,moderate impairment ( nmbr to < nmbr ),C0053917;C0205081;C0221099;C0684336;C1334884;C1881878;C4049705;C4049706;C4085643;C4321335
1,moderate ( nmbr risk factor ),C0035648;C0053917;C0205081;C1334884;C1881878;C4049705;C4049706;C4085643;C4321335
1,mild impairment ( nmbr to < nmbr ),C0053917;C0221099;C0684336;C1334884;C2945599
1,metabolic syndrome ( > nmbr of nmbr characteristics ),C0053917;C0524620;C1334884;C1521970
1,medical therapy only ( n = nmbr ),C0053917;C0205171;C0418981;C1334884;C1720467
1,medical therapy ( n = nmbr ),C0053917;C0418981;C1334884
1,mean score on dasnmbr - nmbr ( crp ) ^,C0053917;C1334884;C3533236;C3890735;C4048285
1,mean ( sd ) dasnmbr - nmbr ( esr ) *,C0053917;C0444504;C1334884;C2347634;C2348143;C2699239;C3811131
1,mases ( nmbr - nmbr )  mean ( sd ),C0053917;C0444504;C1334884;C2347634;C2348143;C2699239
1,low - dose rivaroxaban plus aspirin ( n = nmbr ),C0053917;C0332287;C1334884;C1739768;C2608320
1,losartan n = nmbr,C0053917;C0126174;C1334884
1,llv wlalil nmbr statin,C0053917;C0360714;C1334884
1,level nmbr immobility § | |,C0053917;C0231441;C0441889;C0456079;C1334884;C1547707;C2946261
1,less than nmbr %,C0053917;C0439092;C1334884
1,left ventricular ejection fraction within previous nmbr mo |,C0026544;C0053917;C0205156;C0332177;C0428772;C0488728;C1334884;C1552607
1,leflunomide ( mean dose : nmbr . nmbr mg / day ),C0053917;C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C1334884;C2347634;C2348143
1,lebrikizumab ( n = nmbr ),C0053917;C1334884;C2981360
1,ldl particle size ( week nmbr ),C0053917;C0332174;C0439230;C1334884;C3641256
1,ldl - c < nmbr . nmbr mmol / l,C0053917;C1334884;C1532563
1,latin america hr ( nmbr % cl ),C0023122;C0053917;C0596019;C1334884
1,kim nmbr ( pg / ml ),C0053917;C0439297;C1334884
1,jsn score  mean nmbr sd,C0053917;C0444504;C0449820;C1334884;C2347634;C2348143;C2699239;C4050231
1,ivabradine ( n = nmbr ),C0053917;C0257190;C1334884
1,intervention group ( n = nmbr ),C0053917;C0184661;C0441848;C0886296;C1273869;C1334884
1,intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),C0053917;C0205103;C1334884;C1550465;C2827755;C3889971
1,interleukin - nmbr ( ng / l ),C0021764;C0053917;C0439297;C1334884;C1527200
1,infliximab nmbr mg / kg,C0053917;C0439272;C0666743;C1334884
1,infliximab - naive ( n = nmbr ),C0053917;C0666743;C1334884
1,ind / glynmbr / nmbr pg o . d . n = nmbr,C0053917;C1334884;C2827928;C4049864
1,in ibdq total score at week nmbr  mean [se],C0036919;C0053917;C0332174;C0439175;C0439230;C0439810;C0444504;C1334884;C2347634;C2348143;C2964552;C3533236
1,impaired fasting glucose level ( n = nmbr ),C0053917;C0202045;C0221099;C0441889;C0456079;C1272092;C1334884;C1547707;C2946261
1,hyperkalemia ( > nmbr . nmbr meq / l ),C0020461;C0053917;C0439375;C1334884;C4552983
1,hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr ),C0053917;C0065879;C1334884
1,hospital factor # nmbr,C0019994;C0053917;C1334884;C1510665;C1521761;C2827422
1,hoehn and yahr stage ( range  nmbr - nmbr ),C0053917;C0205390;C1300072;C1306673;C1334884;C1514721;C2348147;C3542016
1,hispanic ( n = nmbr ),C0053917;C0086409;C1334884
1,high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),C0053917;C0205250;C1299351;C1334884;C2700149;C3887512;C3889660;C4321237;C4522209
1,hfpef ( ef n nmbr )  ( % ),C0053917;C1334884
1,hemorrhagic stroke ( n = nmbr ),C0053917;C0553692;C1334884
1,hemoglobin  g nmbr nmbr,C0053917;C1319312;C1334884
1,hbanmbrc nmbr - < = nmbr %,C0053917;C1334884
1,hbanmbrc nmbr % - < nmbr % ( n - nmbr ),C0053917;C1334884
1,hbalc > = nmbr % ( n - nmbr ),C0053917;C1334884
1,hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr  nmbr . nmbr ),C0053917;C0596019;C1334884;C2985465
1,haq - di score ( nmbr - nmbr ),C0053917;C0449820;C1334884;C3826998;C4050231;C4321476
1,glyburide ( n = nmbr ),C0017628;C0053917;C1334884
1,galectin - nmbr ( ng / ml ),C0053917;C0439275;C0607430;C1334884
1,former smoker ( n = nmbr ),C0053917;C0337671;C1334884
1,former n z nmbr,C0053917;C0205156;C0750523;C1334884
1,filtration rate nmbr - nmbr,C0016107;C0053917;C0871208;C1334884;C1521828
1,ezetimibe + simvastatin ( n = nmbr * ),C0053917;C1334884;C1532737
1,exenatide n = nmbr,C0053917;C0167117;C1334884
1,evomab ( n = nmbr ),C0053917;C1334884
1,evenls per nmbr  nmbr palienl - years,C0053917;C0439234;C1334884
1,europe nmbr ( n = nmbr ),C0015176;C0053917;C1334884
1,estimated glomerular filtration rate ( mdrd )  ml / min / nmbr . nmbrmnmbr,C0053917;C0439445;C1334884;C3811844;C3839656
1,estimated creatinine clearance < nmbr ml / min *,C0053917;C0439445;C0750572;C0812399;C1334884
1,estimated * creatinine clearance < nmbr mlvmin  %,C0053917;C0750572;C0812399;C1334884
1,endothelin nmbr ( pg / ml ),C0053917;C0079284;C0439297;C1334884
1,endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,C0031638;C0053917;C0332307;C1134681;C1334884;C1547052;C1656262;C2266875;C3539996
1,elevated hscrp > nmbr mg / l  n ( % ),C0053917;C0205250;C0439268;C1334884;C3163633
1,elevated creatinine ( > nmbr pmol / l ),C0053917;C0151578;C0439284;C0700225;C1334884
1,elevated at wk nmbr — no . ( % ) nmbr,C0053917;C0205250;C0332174;C0439230;C1334884;C3163633
1,elderly ( > nmbr years ),C0001792;C0053917;C0439234;C1334884;C1999167
1,egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr  n ( % ),C0053917;C0369637;C0439445;C0441923;C1334884
1,duration of last qualifying episode of atrial fibrillation > nmbr days,C0004238;C0053917;C0332189;C0344434;C0439228;C0449238;C1334884;C1514624;C1963067;C2926735
1,dlqi  nmbr - nmbr *,C0053917;C1334884;C3899393
1,disease duration nmbr to bnmbr years ( n = nmbr ),C0053917;C0439234;C0872146;C1334884
1,denosumab ( n = nmbr ),C0053917;C1334884;C1690432
1,days of study - drug administration ( % ) * * nmbr day,C0053917;C0150270;C1334884;C2826182;C3469597
1,dactylitis count ( nmbr - nmbr )  mean ( sd ),C0053917;C0239161;C0444504;C0750480;C1334884;C1705566;C2347634;C2348143;C2699239
1,cyclosporine ( n = nmbr ),C0010592;C0010594;C0053917;C1334884
1,csf nmbrs - hydroxy -,C0053917;C1334884;C3540512;C3889436
1,crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l )  n ( % ),C0053917;C0086045;C1334884;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
1,crp ( mg / l ) : < nmbr,C0053917;C0439268;C1334884;C3890735;C4048285
1,crp ( mg / dl ) < nmbr . nmbr,C0053917;C0439269;C1334884;C3890735;C4048285
1,creatinine ≥ nmbr . nmbr mg / dl,C0010294;C0053917;C0439269;C1334884;C1561535
1,creatinine clearance ， : : nmbr ml / min  %,C0053917;C0439445;C0812399;C1334884
1,conventional treatment ( n = nmbr ),C0053917;C1334884;C2945704
1,combined n = nmbr,C0053917;C0205195;C1334884
1,chondroitin sulfate ( n = nmbr ),C0008466;C0053917;C1334884
1,cholesterol  ( . nmbr . nmbr mmol / l )  n ( % ),C0008377;C0053917;C1334884;C1532563
1,chd eze / simva ( n = nmbr],C0053917;C0280604;C1334884;C3542407
1,certolizumab group ( n = nmbr ),C0053917;C0441848;C1334884;C1872109
1,celecoxib ( n = nmbr ),C0053917;C0538927;C1334884
1,candesartan nmbr / nmbr,C0053917;C0717550;C1334884
1,cancer ( n = nmbr ),C0006826;C0053917;C0998265;C1306459;C1334884
1,calculated ldl - c in nmbr classes,C0053917;C0444686;C0456387;C1334884;C1441506;C1518526;C1705943;C4019422
1,cabg > nmbr month ago,C0010055;C0053917;C0332177;C0439231;C1334884
1,bsa > nmbr %  n ( % ) t,C0053917;C1334884
1,bosentan ( n = nmbr ),C0053917;C0252643;C1334884
1,bmi kg - m - nmbr,C0053917;C0578022;C1334884;C1532718
1,bmi ( nmbr . nmbr  nmbr . nmbr ),C0053917;C0578022;C1334884
1,blood leukocyte count ( nmbr cells per l ),C0023508;C0023516;C0053917;C0347983;C0427512;C1334884
1,blood eosinophil count ( nmbr cells per l ),C0053917;C0200638;C1334884
1,biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl )  na,C0005516;C0053917;C0205251;C0219433;C0439275;C1334884;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
1,azathioprine ( n = nmbr ),C0004482;C0053917;C1334884
1,at least nmbr severe flare,C0053917;C0205082;C1334884;C1517205;C3540542;C4050465;C4050466
1,at least nmbr flare,C0053917;C1334884;C1517205;C3540542
1,asia - pacific hr ( nmbr % cl ),C0003980;C0053917;C0596019;C1334884
1,apolipoproiein anmbr ( tng / nmbr ),C0053917;C1334884
1,apoa - nmbr  g / l,C0003592;C0053917;C0439294;C0456615;C0523508;C1334884;C4553344;C4553379
1,anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ),C0053917;C1334884
1,anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr ),C0053917;C1334884
1,ankle - brachial index < nmbr . nmbr — no . ( % ),C0053917;C1328319;C1334884;C3888326
1,alteplase group ( n = nmbr ),C0032143;C0053917;C0441848;C1334884
1,alteplase ( n = nmbr ),C0032143;C0053917;C1334884
1,all with coenzyme qnmbr ( n = nmbr  nmbr ),C0009235;C0053917;C1334884
1,all completers ( n nmbr nmbr ),C0053917;C1334884
1,aliskiren ( n = nmbr ),C0053917;C1120110;C1334884
1,aggressive ( n = nmbr ),C0001807;C0053917;C0580822;C1334884
1,age [years] ( interaction : p = nmbr . nmbr ),C0053917;C1334884;C1510829;C1704675
1,age < nmbr years — no . ( % ),C0053917;C1334884;C1510829
1,age ( yrs ) < nmbr,C0001779;C0053917;C1334884
1,age ( years ) : nmbr - < nmbr,C0053917;C1334884;C1510829
1,adl subscale ( range  nmbr - nmbr ) *,C0001288;C0053917;C1334884;C1420005;C1514721;C2348147;C3542016
1,acute coronary syndrome nmbr,C0053917;C0948089;C1334884
1,a / v ( n = nmbr ),C0053917;C1272460;C1334884
1,> nmbr vessels with > nmbr % stenosis,C0053917;C0679403;C1334884
1,> nmbr servings / wk ( n = nmbr ),C0053917;C0332174;C0439230;C1334884;C1519269
1,> nmbr oral agents,C0053917;C0442027;C0450442;C1254351;C1334884;C1521826;C4521986
1,> nmbr : obese class iii,C0053917;C1319441;C1334884
1,> nmbr . nmbrmmol / l ( n = nmbr ),C0053917;C1334884
1,< nmbr years eze / simva,C0053917;C0439234;C1334884
1,< nmbr months  n ( % ),C0053917;C0439231;C1334884
1,< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),C0053917;C0439445;C1334884
1,< nmbr . nmbr mmol / liter triglyceride level,C0053917;C0428475;C0439190;C0475211;C1334884
1,< nmbr . nmbr mm hg diastolic blood pressure,C0053917;C0428883;C0439475;C1305849;C1334884
1,( nmbr % ell ' ll  * non - hdl - c,C0053917;C1334884;C1427925;C3273466
1,( nmbr % cl ) interaction,C0053917;C0596019;C1334884;C1704675
1,( % ) nmbr - nmbr,C0053917;C1334884
1,( %  nmbr % cl ),C0053917;C0596019;C1334884
1,( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),C0053917;C0439269;C1334884;C1532563
0,treated hypertension :,C0020538;C1522326;C1963138
0,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
0,previous hypertension,C0020538;C0205156;C1552607;C1963138
0,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
0,hypertension and left ventricular hypertrophy,C0020538;C1963138
0,hypertension : no ( n = nmbr ),C0020538;C1963138
0,hypertension ( n 二 nmbr ),C0020538;C0053917;C1334884;C1963138
0,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
0,duration of hypertension  n ( % ),C0020538;C0449238;C1963138;C2926735
